磁共振成像在肥厚性心肌病中的临床应用研究
|
摘要
目的：肥厚性心肌病(Hypertrophic Cardiomyopathy, HCM)是已知病因明确的一种遗传性心血管疾病,是已知心源性猝死(Sudden Cardiac Death, SCD)最常见的原因。室性心律失常在HCM中很常见,尤其是非持续性室性心动过速(Non-sustained Ventricular Tachycardia, NSVT)更是HCM发生SCD最常见的诱因。本研究的目的是评估汉族中国人群的肥厚性心肌病患者发生严重室性心律失常与心脏磁共振钆对比剂延迟强化(Late Gadolinium Enhancement, LGE)之间的相关性。
资料与方法：本研究纳入至我院行CMR检查的连续310例HCM患者,并根据有无严重室性心律失常分为两组。室性心律失常包括频发室性早搏、室性二联律、NSVT以及持续性室性心动过速。代表心肌纤维化的LGE的量化方法定义为信号增强区域影像密度超过同一层面远离部位正常心肌的影像密度2个标准差,并以占左心室心肌的百分比表示(%/LV)。将LGE阳性患者按严重程度分为轻度(1%-25%/LV)、中度(25%-50%/LV)和重度(>50%/LV)三组。为评估左心室不同区域/区段的心室壁厚度和LGE程度等参数对室性心律失常的影响,将左心室按17节段法模型分为不同区域/区段进行统计分析。用单因素和多因素Logistic回归分析来判定NSVT的危险因素,用ROC曲线用来评估筛选出的危险因素对NSVT的诊断价值。
结果：室壁增厚和LGE在室间隔相关节段明显多于其他节段,心室壁最大厚度与室壁肥厚节段数均与LGE呈明显相关性(r=0.56,p<0.01和r=0.51,p<0.01)。对最大室壁厚度>30mm的室壁极度肥厚区域多位于室间隔的基底段和中间段,有室性心律失常组比无室性心律失常组有更多的患者和节段出现室壁异常肥厚(p<0.01)。在前壁和侧壁区域,不论是基底段、中间段或心尖段,有室性心律失常组的室壁平均厚度均较无室性心律失常组增加(p<0.05)。进一步将心律失常细分后有NSVT患者的平均室壁厚度在后室间隔、前壁和侧壁均较无心律失常患者增加(p=0.024,p=0.004和0.001)。LGE阳性出现在217例(70%)患者中,约占左心室心肌质量约12.0±9.8%(范围1.4%到57.8%)；分别有94例(43%)、83例(38%)和40例(18%)例患者属于延迟强化轻度组、中度组和重度组。LGE主要分布于室间隔各节段以及室间隔与前壁和下壁移行交界区域(64%),有室性心律失常组患者的LGE严重程度在所有区段的均较无室性心律失常组为重,差异有统计学显著性(p<0.01)。频发室性早搏的发病率在不同LGE分组中均无显著性差异；室性二联律仅在LGE中度组和重度组有差异,而在LGE阴性和轻度组及中度组间无显著性差异；NSVT在所有不同程度阳性组及阴性组间均有显著性差异。总体LGE阳性患者发生NSVT的风险是阴性患者的7.4倍,NSVT的发病率与LGE严重程度的相关系数为0.68。多因素Logistic回归分析中,仅有左心房容积指数和LGE严重程度是NSVT的独立预测因子,其各自的ROC曲线下面积分别是0.633和0.798。LGE取临界值为11.5%/LV时预测NSVT的敏感性和特异性分别是67.4%和85.1%。
结论：HCM心肌肥厚节段与CMR的LGE分布趋势相关,室性心律失常的发生与LGE阳性及其严重程度有显著相关性。左心房容积指数和LGE严重程度是NSVT的独立预测因子。
目的：肥厚性心肌病(Hypertrophic Cardiomyopathy, HCM)是一种最常见的遗传性心血管疾病,可以导致心源性猝死(Sudden Cardiac Death, SCD)、心力衰竭和中风等不良预后终点事件。这些症状主要是由于恶性心律失常或/和左心室流出道梗阻所致,而心肌纤维化及心肌瘢痕被认为是导致严重恶性心律失常和心力衰竭以及心房颤动并发症等的潜在病理基础,是HCM终点事件的独立预测因子。心脏磁共振成像延迟强化(Cardiac Magnetic Resonance Late Gadolinium Enhancement, LGE-CMR)可以无创性检测心肌纤维化,在HCM的临床实践中发挥着非常重要的作用。本研究拟通过前瞻性随访,明确LGE对HCM终点事件的预后价值。
资料与方法：从2010年4月至2012年5月,对所有来我院行CMR检查的HCM患者进行筛选和跟踪随访。HCM的诊断标准参照既往文献报道,行CMR检查之前已接受左心室流出道减压手术的患者被排除。每隔3-6个月间歇对所有患者进行随访,只有被纳入研究之后出现的新发事件才被分析和归类为主要或次要终点事件。主要终点事件包括：心源性死亡、心脏移植、SCD及SCD抢救后复苏、持续性室性心动过速、心室颤动以及植入性心律转复除颤器(Implantable Cardiac Defibrillator,ICD)的适度除颤；次要终点事件包括：进行性心力衰竭症状、非计划性心源性入院以及发生非持续性室性心动过速(Non-sustained Ventricular Tachycardia, NSVT)等。CMR-LGE的量化方法以占左心室心肌的百分比表示(%/LV),并将LGE阳性患者按严重程度分为轻度(1%-25%/LV)、中度(25%-50%/LV)和重度(>50%/LV)三组。Kaplan-Meier生存率曲线用来比较不同LGE组间免终点事件生存率,和log-rank检验用来比较组间差异；多因素Cox比例风险回归分析用来评估联合终点事件的独立危险因素；ROC曲线用来评估LGE对终点事件的预测价值。为评估肥厚位置对联合终点事件的影响,将患者分为肥厚性梗阻型心肌病(Hypertrophic Obstructive Cardiomyopathy, HOCM)、非梗阻型和心尖肥厚型,进行生存分析的对比；随访期间接受左心室流出道减压手术的80例患者与未接受手术治疗的HOCM患者也进行如上生存分析,并比较组间差异。
结果：420例患者最后共392例HCM患者完成了随访,其中包括80例患者随访期间接受了左室流出道减压手术将进行单独分析,随访时间528±137天(范围158-1379天),随访率93%。自然病程的312例患者中心肌纤维化阳性患者有218例(70%),心肌纤维化阴性组有94例患者。LGE阳性患者在纽约心功能分级、左心室心肌质量、平均室壁厚度、极度室壁肥厚(>30mm)、心房颤动和NSVT发病率等方面较LGE阴性患者有显著性差异。共有35例患者(11.2%)达到了主要终点事件,LGE阴性组和阳性组分别有5例和30例(5.3%比13.8%,p<0.05)；其中3例心源性死亡、1例心脏移植、9例持续性室性心动过速和心室颤动的患者均发生在LGE阳性组。77例患者(24.7%)发生了次要终点事件,LGE阴性组和阳性组分别有10例和67例(10.6%比30.7%,p<0.05)。K-M生存曲线显示患者免终点事件生存率(主要和次要)都随着LGE严重程度的增加而降低。Cox比例风险回归分析显示左心室流出道梗阻(LVOTO)和LGE阳性是主要终点事件的独立危险因素,而LGE阳性是次要终点事件的唯一独立危险因素。ROC曲线显示LGE代表的心肌纤维化对不良终点事件的预测能力满意。HOCM患者的联合终点事件生存率较非梗阻型和心尖肥厚型为差,其中接受流出道减压手术的HOCM患者的联合免终点事件生存率要好于未接受减压手术的患者。
结论：CMR检测到HCM的心肌纤维化可以对联合不良终点事件作出满意的预后评估,有左心室流出道梗阻患者预后较差,但接受流出道减压手术可以改善预后。
Background Hypertrophic Cardiomyopathy (HCM) is the most common inherited genetic cardiovascular disease and the most frequent cause of sudden cardiac death (SCD) in young people. Ventricular arrhythmias,especially non-sustained ventricular tachycardia (NSVT) or sustained VT, are believed to be the main cause of SCD. The aim of this study was to evaluate the correlation between ventricular arrhythmias and late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) in a large Chinese HCM cohort.
Methods310patients were enrolled and divided into two groups regarding ventricular arrhythmias, including frequent premature ventricular contractions (PVCs), couplets and NSVT. The LGE was defined as those with image intensities>2SD above the mean of image intensities in a remote myocardial region in the same section. Total volume of LGE was calculated by summing the planimetered areas of LGE in all short-axis slices and was expressed as a proportion of total LV myocardium (%/LV). LGE positive patients were divided into three groups:mild (1%-25%/LV), moderate (25%-50%/LV) and severe (>50%/LV). Left ventricle was divided into different segments according to American Heart Association17segment model. Prevalence of ventricular arrhythmias was calculated regarding LGE amount. Univariate and multivariate-Logistic regression was analyzed to figure out risk factors of NSVT. Receiver operating curve (ROC) was applied to assess the diagnostic capability of risk determinants on NSVT.
Results Left ventricular hypertrophy and the myocardial fibrosis were mainly located in interventricular septum (IVS), and there is good correlation between the segments of hypertrophy and the spectrum of LGE. There were more extreme hypertrophy (>30mm) in the IVS than other segments. Patients with ventricular arrhythmias had more extreme hypertrophic segments than those without ventricular arrhythmias, also the average wall thickness in the anterior and inferior segments of ventricular arrhythmias groupwere larger than the negative group. LGE was present in217(70%) patients, occupying12.0±9.8%(range1.4%to57.8%) of LV myocardium. There were94cases (43%),83cases (38%) and40cases (18%) in the mild, moderate and severe LGE groups, respectively. Prevalence of PVCs didn't show significant difference among groups, while prevalence of couplets showed statistical significance only between the moderate and severe LGE groups. Prevalence of NSVT arose as LGE amount increased with statistical significance among all groups. LGE positive patients had a7-fold higher risk of NSVT than those without, and the correlation coefficient between them was0.680. In multivariate analysis, LA diameter and LGE amount were independent determinants of NSVT, and their area under ROC curve were0.633and0.798, respectively. The cut-off value of LGE amount as11.5%had a sensitivity of67.4%and specificity of85.1%to predict NSVT.
Conclusions Myocardial fibrosis was correlated with the spectrum of hypertrophic segments, and prevalence of ventricular arrhythmias is correlated with LGE amount.Both LGE amount and LA diameter are independent predictors of NSVT.
Background Hypertrophic cardiomyopathy is the most common inherited genetic cardiovascular disease and the main cause of sudden cardiac death (SCD) in the young, it can also cause other hard end points such as heart failure death and stroke. Themechanism is believed due to malignant ventricular and/or left ventricular outflow tract obstruction (LVOTO), and myocardial fibrosis was thought to be the pathological substrate, as an independent determinant of adverse cardiac events. This study is aim to evaluate the prognostic role of myocardial fibrosis detected by cardiac magnetic resonance late gadolinium enhancement(LGE-CMR) in the mid-term follow up of HCM.
Methods From April2010to May2012, we followed up all HCM patients come to our hospital every3to6month intervals, with exclusion of those who had prior gradient reduction therapy. Only new events occurred during the follow up were regards as end points, which primary end points included cardiovascular death, heart transplantation, SCD/aborted SCD, sustained ventricular tachycardia, ventricular fibrillation and appropriate implantable cardiac defibrillator (ICD) discharge; and secondary end point included progressive heart failure, unplanned cardiovascular hospitalization and non-sustained ventricular tachycardia (NSVT). The extent of LGE was divided into three groups:mild (1%-25%/LV), moderate (25%-50%/LV) and severe (>50%/LV). Kaplan-Meier curves and log-rank test were used to estimate the events free survival distributions and compare the difference among different LGE groups. A multivariable Cox proportional hazard model was constructed with a forward selection procedureto estimate the hazard ratio (HR) for the presence or absence of fibrosis and to estimate the effect on the outcomes of increased amounts of fibrosis. Hypertrophic obstructive cardiomyopathy (HOCM) patients were also compared with non-obstructive patients for the events free survival curves, and patients received gradient reduction therapy were compared with those HOCM who didn't receive any surgical procedure.
Results Totally392patients were followed up; including80patients received gradient reduction therapy during the follow-up. Among the312natural procession patients, LGE was observed in218patients (70%). There were statistical significance on NYHA cardiac class, left ventricular mass, average wall thickness, extreme hypertrophy (>30mm), prevalence of atrial fibrillation and NSVT between patients with and without LGE.35patients reached the primary end points, including5in the LGE negative and30in the LGE positive group (5.3%vs.13.8%, p<0.05); while3cardiac deaths,1heart transplantation and9sustained ventricular tachycardia/ventricular fibrillation were all happened in the fibrosis group.77patients reached the secondary end points, including10in the LGE negative and67in the LGE positive (10.6%vs.30.7, p<0.05). There was statistical significance among Kaplan-Meier survival curves among different LGE groups, no matter regarding to primary or secondary end points. The LVOTO and LGE positive were the independent determinants for the primary end points after Cox proportional hazard regression, while only LGE was the risk factor for the secondary end points. There were statistical significance among the events free survival among HOCM, non-obstructive and apical HCM patients, and patients received gradient reduction therapy had better prognosis than those HOCM patients who didn't received intervention.
Conclusion Myocardial fibrosis detected by CMR can play an important prognostic role in HCM. The prognosis of HOCM was worse than the non-obstructive HCM patients, while receive gradient reduction therapy would benefit the mid-term survival.
资料与方法：本研究纳入至我院行CMR检查的连续310例HCM患者,并根据有无严重室性心律失常分为两组。室性心律失常包括频发室性早搏、室性二联律、NSVT以及持续性室性心动过速。代表心肌纤维化的LGE的量化方法定义为信号增强区域影像密度超过同一层面远离部位正常心肌的影像密度2个标准差,并以占左心室心肌的百分比表示(%/LV)。将LGE阳性患者按严重程度分为轻度(1%-25%/LV)、中度(25%-50%/LV)和重度(>50%/LV)三组。为评估左心室不同区域/区段的心室壁厚度和LGE程度等参数对室性心律失常的影响,将左心室按17节段法模型分为不同区域/区段进行统计分析。用单因素和多因素Logistic回归分析来判定NSVT的危险因素,用ROC曲线用来评估筛选出的危险因素对NSVT的诊断价值。
结果：室壁增厚和LGE在室间隔相关节段明显多于其他节段,心室壁最大厚度与室壁肥厚节段数均与LGE呈明显相关性(r=0.56,p<0.01和r=0.51,p<0.01)。对最大室壁厚度>30mm的室壁极度肥厚区域多位于室间隔的基底段和中间段,有室性心律失常组比无室性心律失常组有更多的患者和节段出现室壁异常肥厚(p<0.01)。在前壁和侧壁区域,不论是基底段、中间段或心尖段,有室性心律失常组的室壁平均厚度均较无室性心律失常组增加(p<0.05)。进一步将心律失常细分后有NSVT患者的平均室壁厚度在后室间隔、前壁和侧壁均较无心律失常患者增加(p=0.024,p=0.004和0.001)。LGE阳性出现在217例(70%)患者中,约占左心室心肌质量约12.0±9.8%(范围1.4%到57.8%)；分别有94例(43%)、83例(38%)和40例(18%)例患者属于延迟强化轻度组、中度组和重度组。LGE主要分布于室间隔各节段以及室间隔与前壁和下壁移行交界区域(64%),有室性心律失常组患者的LGE严重程度在所有区段的均较无室性心律失常组为重,差异有统计学显著性(p<0.01)。频发室性早搏的发病率在不同LGE分组中均无显著性差异；室性二联律仅在LGE中度组和重度组有差异,而在LGE阴性和轻度组及中度组间无显著性差异；NSVT在所有不同程度阳性组及阴性组间均有显著性差异。总体LGE阳性患者发生NSVT的风险是阴性患者的7.4倍,NSVT的发病率与LGE严重程度的相关系数为0.68。多因素Logistic回归分析中,仅有左心房容积指数和LGE严重程度是NSVT的独立预测因子,其各自的ROC曲线下面积分别是0.633和0.798。LGE取临界值为11.5%/LV时预测NSVT的敏感性和特异性分别是67.4%和85.1%。
结论：HCM心肌肥厚节段与CMR的LGE分布趋势相关,室性心律失常的发生与LGE阳性及其严重程度有显著相关性。左心房容积指数和LGE严重程度是NSVT的独立预测因子。
目的：肥厚性心肌病(Hypertrophic Cardiomyopathy, HCM)是一种最常见的遗传性心血管疾病,可以导致心源性猝死(Sudden Cardiac Death, SCD)、心力衰竭和中风等不良预后终点事件。这些症状主要是由于恶性心律失常或/和左心室流出道梗阻所致,而心肌纤维化及心肌瘢痕被认为是导致严重恶性心律失常和心力衰竭以及心房颤动并发症等的潜在病理基础,是HCM终点事件的独立预测因子。心脏磁共振成像延迟强化(Cardiac Magnetic Resonance Late Gadolinium Enhancement, LGE-CMR)可以无创性检测心肌纤维化,在HCM的临床实践中发挥着非常重要的作用。本研究拟通过前瞻性随访,明确LGE对HCM终点事件的预后价值。
资料与方法：从2010年4月至2012年5月,对所有来我院行CMR检查的HCM患者进行筛选和跟踪随访。HCM的诊断标准参照既往文献报道,行CMR检查之前已接受左心室流出道减压手术的患者被排除。每隔3-6个月间歇对所有患者进行随访,只有被纳入研究之后出现的新发事件才被分析和归类为主要或次要终点事件。主要终点事件包括：心源性死亡、心脏移植、SCD及SCD抢救后复苏、持续性室性心动过速、心室颤动以及植入性心律转复除颤器(Implantable Cardiac Defibrillator,ICD)的适度除颤；次要终点事件包括：进行性心力衰竭症状、非计划性心源性入院以及发生非持续性室性心动过速(Non-sustained Ventricular Tachycardia, NSVT)等。CMR-LGE的量化方法以占左心室心肌的百分比表示(%/LV),并将LGE阳性患者按严重程度分为轻度(1%-25%/LV)、中度(25%-50%/LV)和重度(>50%/LV)三组。Kaplan-Meier生存率曲线用来比较不同LGE组间免终点事件生存率,和log-rank检验用来比较组间差异；多因素Cox比例风险回归分析用来评估联合终点事件的独立危险因素；ROC曲线用来评估LGE对终点事件的预测价值。为评估肥厚位置对联合终点事件的影响,将患者分为肥厚性梗阻型心肌病(Hypertrophic Obstructive Cardiomyopathy, HOCM)、非梗阻型和心尖肥厚型,进行生存分析的对比；随访期间接受左心室流出道减压手术的80例患者与未接受手术治疗的HOCM患者也进行如上生存分析,并比较组间差异。
结果：420例患者最后共392例HCM患者完成了随访,其中包括80例患者随访期间接受了左室流出道减压手术将进行单独分析,随访时间528±137天(范围158-1379天),随访率93%。自然病程的312例患者中心肌纤维化阳性患者有218例(70%),心肌纤维化阴性组有94例患者。LGE阳性患者在纽约心功能分级、左心室心肌质量、平均室壁厚度、极度室壁肥厚(>30mm)、心房颤动和NSVT发病率等方面较LGE阴性患者有显著性差异。共有35例患者(11.2%)达到了主要终点事件,LGE阴性组和阳性组分别有5例和30例(5.3%比13.8%,p<0.05)；其中3例心源性死亡、1例心脏移植、9例持续性室性心动过速和心室颤动的患者均发生在LGE阳性组。77例患者(24.7%)发生了次要终点事件,LGE阴性组和阳性组分别有10例和67例(10.6%比30.7%,p<0.05)。K-M生存曲线显示患者免终点事件生存率(主要和次要)都随着LGE严重程度的增加而降低。Cox比例风险回归分析显示左心室流出道梗阻(LVOTO)和LGE阳性是主要终点事件的独立危险因素,而LGE阳性是次要终点事件的唯一独立危险因素。ROC曲线显示LGE代表的心肌纤维化对不良终点事件的预测能力满意。HOCM患者的联合终点事件生存率较非梗阻型和心尖肥厚型为差,其中接受流出道减压手术的HOCM患者的联合免终点事件生存率要好于未接受减压手术的患者。
结论：CMR检测到HCM的心肌纤维化可以对联合不良终点事件作出满意的预后评估,有左心室流出道梗阻患者预后较差,但接受流出道减压手术可以改善预后。
Background Hypertrophic Cardiomyopathy (HCM) is the most common inherited genetic cardiovascular disease and the most frequent cause of sudden cardiac death (SCD) in young people. Ventricular arrhythmias,especially non-sustained ventricular tachycardia (NSVT) or sustained VT, are believed to be the main cause of SCD. The aim of this study was to evaluate the correlation between ventricular arrhythmias and late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) in a large Chinese HCM cohort.
Methods310patients were enrolled and divided into two groups regarding ventricular arrhythmias, including frequent premature ventricular contractions (PVCs), couplets and NSVT. The LGE was defined as those with image intensities>2SD above the mean of image intensities in a remote myocardial region in the same section. Total volume of LGE was calculated by summing the planimetered areas of LGE in all short-axis slices and was expressed as a proportion of total LV myocardium (%/LV). LGE positive patients were divided into three groups:mild (1%-25%/LV), moderate (25%-50%/LV) and severe (>50%/LV). Left ventricle was divided into different segments according to American Heart Association17segment model. Prevalence of ventricular arrhythmias was calculated regarding LGE amount. Univariate and multivariate-Logistic regression was analyzed to figure out risk factors of NSVT. Receiver operating curve (ROC) was applied to assess the diagnostic capability of risk determinants on NSVT.
Results Left ventricular hypertrophy and the myocardial fibrosis were mainly located in interventricular septum (IVS), and there is good correlation between the segments of hypertrophy and the spectrum of LGE. There were more extreme hypertrophy (>30mm) in the IVS than other segments. Patients with ventricular arrhythmias had more extreme hypertrophic segments than those without ventricular arrhythmias, also the average wall thickness in the anterior and inferior segments of ventricular arrhythmias groupwere larger than the negative group. LGE was present in217(70%) patients, occupying12.0±9.8%(range1.4%to57.8%) of LV myocardium. There were94cases (43%),83cases (38%) and40cases (18%) in the mild, moderate and severe LGE groups, respectively. Prevalence of PVCs didn't show significant difference among groups, while prevalence of couplets showed statistical significance only between the moderate and severe LGE groups. Prevalence of NSVT arose as LGE amount increased with statistical significance among all groups. LGE positive patients had a7-fold higher risk of NSVT than those without, and the correlation coefficient between them was0.680. In multivariate analysis, LA diameter and LGE amount were independent determinants of NSVT, and their area under ROC curve were0.633and0.798, respectively. The cut-off value of LGE amount as11.5%had a sensitivity of67.4%and specificity of85.1%to predict NSVT.
Conclusions Myocardial fibrosis was correlated with the spectrum of hypertrophic segments, and prevalence of ventricular arrhythmias is correlated with LGE amount.Both LGE amount and LA diameter are independent predictors of NSVT.
Background Hypertrophic cardiomyopathy is the most common inherited genetic cardiovascular disease and the main cause of sudden cardiac death (SCD) in the young, it can also cause other hard end points such as heart failure death and stroke. Themechanism is believed due to malignant ventricular and/or left ventricular outflow tract obstruction (LVOTO), and myocardial fibrosis was thought to be the pathological substrate, as an independent determinant of adverse cardiac events. This study is aim to evaluate the prognostic role of myocardial fibrosis detected by cardiac magnetic resonance late gadolinium enhancement(LGE-CMR) in the mid-term follow up of HCM.
Methods From April2010to May2012, we followed up all HCM patients come to our hospital every3to6month intervals, with exclusion of those who had prior gradient reduction therapy. Only new events occurred during the follow up were regards as end points, which primary end points included cardiovascular death, heart transplantation, SCD/aborted SCD, sustained ventricular tachycardia, ventricular fibrillation and appropriate implantable cardiac defibrillator (ICD) discharge; and secondary end point included progressive heart failure, unplanned cardiovascular hospitalization and non-sustained ventricular tachycardia (NSVT). The extent of LGE was divided into three groups:mild (1%-25%/LV), moderate (25%-50%/LV) and severe (>50%/LV). Kaplan-Meier curves and log-rank test were used to estimate the events free survival distributions and compare the difference among different LGE groups. A multivariable Cox proportional hazard model was constructed with a forward selection procedureto estimate the hazard ratio (HR) for the presence or absence of fibrosis and to estimate the effect on the outcomes of increased amounts of fibrosis. Hypertrophic obstructive cardiomyopathy (HOCM) patients were also compared with non-obstructive patients for the events free survival curves, and patients received gradient reduction therapy were compared with those HOCM who didn't receive any surgical procedure.
Results Totally392patients were followed up; including80patients received gradient reduction therapy during the follow-up. Among the312natural procession patients, LGE was observed in218patients (70%). There were statistical significance on NYHA cardiac class, left ventricular mass, average wall thickness, extreme hypertrophy (>30mm), prevalence of atrial fibrillation and NSVT between patients with and without LGE.35patients reached the primary end points, including5in the LGE negative and30in the LGE positive group (5.3%vs.13.8%, p<0.05); while3cardiac deaths,1heart transplantation and9sustained ventricular tachycardia/ventricular fibrillation were all happened in the fibrosis group.77patients reached the secondary end points, including10in the LGE negative and67in the LGE positive (10.6%vs.30.7, p<0.05). There was statistical significance among Kaplan-Meier survival curves among different LGE groups, no matter regarding to primary or secondary end points. The LVOTO and LGE positive were the independent determinants for the primary end points after Cox proportional hazard regression, while only LGE was the risk factor for the secondary end points. There were statistical significance among the events free survival among HOCM, non-obstructive and apical HCM patients, and patients received gradient reduction therapy had better prognosis than those HOCM patients who didn't received intervention.
Conclusion Myocardial fibrosis detected by CMR can play an important prognostic role in HCM. The prognosis of HOCM was worse than the non-obstructive HCM patients, while receive gradient reduction therapy would benefit the mid-term survival.
引文
[1]Barry J. Maron, Maron MS. Hypertrophic cardiomyopathy[J]. The Lancet, 2013,381(9862):242-255.
[2]Schwartz PJ, Corrado D. Sudden Cardiac Death in Young Competitive Athletes[J]. Eur Heart J,2012,33(16):1986-1988.
[3]Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy[J]. Circulation,2010,121(3): 445-456.
[4]Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, Nakajima T, Kawashiro N, Kawana M, Hagiwara N. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2011,57(23):2346-2355.
[5]Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death[J]. World J Cardiol,2010,2(9):289-298.
[6]Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, Abe Y, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy [J]. Magn Reson Imaging,2004,22(2):155-161.
[7]Kunihiko Teraoka, Masaharu Hirano, Ookubo H, Kazuyoshi Sasaki, Hiroaki Katsuyama, Masayuki Amino, Yimihiko Abe, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy [J]. Magn Reson Imaging, 2005,23(5):701.
[8]Prinz C, Schwarz M,Ilie I, Laser KT, Lehmann R, Prinz EM, Bitter T, Vogt J, van Buuren F, Bogunovic N, Horstkotte D, Faber L. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy[J]. Can J Cardiol,2013,29(3):358-363.
[9]Noureldin RA, Liu S, Nacif MS, Judge DP, Halushka MK, Abraham TP, Ho C, Bluemke DA. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2012,14:17.
[10]Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy [J]. Hum Pathol,2013,44(1):133-141.
[11]Giancarlo Todiere, Giovanni Donato Aquaro, Paolo Piaggi, Formisano F, Andrea Barison, Pier Giorgio Masci, Elisabetta Strata, Lorenzo Bacigalupo, Mario Marzilli, Alessandro Pingitore, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2012,60(10):922-929.
[12]Todiere G, Aquaro G, Pingitore A, Barison A, Strata E, Capozza P, Lombardi M. Progression of myocardial fibrosis and functional clinical status in Hypertrophic Cardiomyopathy:a study with cardiac magnetic resonance[J]. Journal of Cardiovascular Magnetic Resonance,2011,13(Suppl 1):P272.
[13]Ho. CY. Hypertrophic Cardiomyopathy in 2012[J]. Circulation Journal, 2012,125:1432-1438.
[14]Uretsky S. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy [J]. Prog Cardiovasc Dis,2012,54(6):512-516.
[15]Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy:correlation with histopathology and prevalence of ventricular tachycardia[J]. J Am Coll Cardiol,2009,54(3):242-249.
[16]White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, Leong-Sit P, Warren H, Thompson T, Drangova M, Krahn A. Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhythmias[J]. Circ Cardiovasc Imaging,2012,5(1):12-20.
[17]Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2012,5(1):119-122.
[18]Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy [J]. Heart, 2012,98(6):438-442.
[19]Ismail TF, Jabbour A, Mallorie A, Cowling T, Das B, Gulati A, Wage R, Pennell D, Prasad S. Role of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in the Risk Stratification of Hypertrophic Cardiomyopathy [J]. J Am Coll Cardiol,2012,59(13):E1581.
[20]Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2008,51(14):1369-1374.
[21]Bunch TJ, Chandrasekaran K, Ehrsam JE, Hammill SC, Urban LH, Hodge DO, Ommen SR, Pellikka PA. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy[J]. Am J Cardiol, 2007,99(6):835-838.
[22]Deborah H. Kwon, Randolph M. Setser, Zoran B. Popovic, Maran Thamilarasan, Srikanth Sola, Paul Schoenhagen, Mario J. Garcia, Scott D. Flamm, Harry M. Lever, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study.[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[23]Nazarian S, Lima JA. Cardiovascular magnetic resonance for risk stratification of arrhythmia in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2008,51(14):1375-1376.
[24]Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy[J]. Circ Heart Fail,2008,1(3): 184-191.
[25]Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,56(11): 875-887.
[26]Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy[J]. Circ Heart Fail,2010,3(1): 51-58.
[27]Strijack B, Ariyarajah V, Soni R, Jassal DS, Greenberg CR, McGregor R, Morris A. Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype[J]. J Cardiovasc Magn Reson,2008,10:58.
[28]Heinrich G. Klues, Andrea Schiffers, Maron. BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy:Morphologic Observations and Significance As Assessed by Two-Dimensional Echocardiography in 600 Patients[J]. J Am Coll Cardiol,1995,36:1699-1708.
[29]Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy [J]. Circulation,1978,58(3):402-408.
[30]Rose A. Evaluation of pathological criteria for diagnosis of hypertrophic cardiomyopathy[J]. Histopathology,1984,8(3):395-406.
[31]Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart A, Council on Clinical Cardiology HF, Transplantation C, Quality of C, Outcomes R, Functional G, Translational Biology Interdisciplinary Working G, Council on E, Prevention. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[32]Andrew C.Y.To, Ashwat Dhillon, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2011,4(10):1123-1137.
[33]Morton G, Chiribiri A, Ishida M, Hussain ST, Schuster A, Indermuehle A, Perera D, Knuuti J, Baker S, Hedstrom E, Schleyer P, O'Doherty M, Barrington S, Nagel E. Quantification of absolute myocardial perfusion in patients with coronary artery disease:comparison between cardiovascular magnetic resonance and positron emission tomography [J]. J Am Coll Cardiol,2012,60(16):1546-1555.
[34]Techasith T, Cury RC. Stress myocardial CT perfusion:an update and future perspective[J]. JACC Cardiovasc Imaging,2011,4(8):905-916.
[35]Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy[J]. J Thorac Cardiovasc Surg,2011,141(2):439-443.
[36]Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2005,45(5):697-704.
[37]Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia[J]. J Am Coll Cardiol,2012,60(20):1993-2004.
[38]Di Salvo G, Pacileo G, Limongelli G, Baldini L, Rea A, Verrengia M, D'Andrea A, Russo MG, Calabro R. Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters[J]. J Am Soc Echocardiogr,2010,23(6):581-590.
[39]Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement[J]. Magn Reson Med,2002,47(2):372-383.
[40]Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy [J]. Dtsch Arztebl Int,2011,108(13):209-215.
[41]Salerno M, Kramer CM. Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance:the future looks bright[J]. J Am Coll Cardiol,2010,56(11):888-889.
[42]Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. Am J Cardiol,2010,106(2): 261-267.
[43]Manuel D. Cerqueira, Neil J. Weissman, Vasken Dilsizian, Alice K. Jacobs, Sanjiv Kaul, Warren K. Laskey, Dudley J. Pennell, John A. Rumberger, Ryan T, Verani MS. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart:A Statement for Healthcare Professionals From the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2002,105(4):539-542.
[44]Nojiri A, Hongo K, Kawai M, Komukai K, Sakuma T, Taniguchi I, Yoshimura M. Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy [J]. J Cardiol,2011,58(3):253-260.
[45]Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2004,43(12): 2260-2264.
[46]Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, Petryka J, Dabrowski M, Kepka C, Ruzyllo W. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy[J]. Eur J Radiol,2010,74(3):149-153.
[47]Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance[J]. JACC Cardiovasc Imaging, 2011,4(2):150-156.
[48]Buechel EV, Kaiser T, Jackson C, Schmitz A, Kellenberger CJ. Normal right- and left ventricular volumes and myocardial mass in children measured by steady state free precession cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson, 2009,11:19.
[49]O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11):867-874.
[50]Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy[J]. Eur Heart J,2009,30(16):2003-2010.
[51]Dumont CA, Monserrat L, Soler R, Rodriguez E, Fernandez X, Peteiro J, Bouzas A, Bouzas B, Castro-Beiras A. Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance[J]. Eur Heart J,2006,27(14):1725-1731.
[52]Matsubara K, Nakamura T, Kuribayashi T, Azuma A, Nakagawa M. Sustained cavity obliteration and apical aneurysm formation in apical hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2003,42(2):288-295.
[53]Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, Schoenberg SO, Sueselbeck T, Germans T, Streitner F, Borggrefe M, Papavassiliu T. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy [J]. J Cardiovasc Magn Reson,2010,12:30.
[54]Tani T, Yagi T, Kitai T, Kim K, Nakamura H, Konda T, Fujii Y, Kawai J, Kobori A, Ehara N, Kinoshita M, Kaji S, Yamamuro A, Morioka S, Kita T, Furukawa Y. Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy [J]. Cardiovasc Ultrasound,2011,9:34.
[55]Pujadas S, Vidal-Perez R, Hidalgo A, Leta R, Carreras F, Barros A, Bayes-Genis A, Subirana MT, Pons-Llado G. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy:a cardiac magnetic resonance imaging study[J]. Eur J Radiol,2010,75(2):88-91.
[56]Papavassiliu T, Germans T, Fluchter S, Doesch C, Suriyakamar A, Haghi D, Suselbeck T, Wolpert C, Dinter D, Schoenberg SO, van Rossum AC, Borggrefe M. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation[J]. J Cardiovasc Magn Reson,2009,11:34.
[57]Sorajja P, Nishimura RA, Gersh BJ, Dearani JA, Hodge DO, Wiste HJ, Ommen SR. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy:a long-term follow-up study[J]. J Am Coll Cardiol,2009,54(3): 234-241.
[58]Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2009,54(3):220-228.
[59]Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy:from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2009,54(3):191-200.
[60]Efthimiadis GK, Pliakos C, Pagourelias ED, Parcharidou DG, Spanos G, Paraskevaidis S, Styliadis IH, Parcharidis G. Hypertrophic cardiomyopathy with midventricular obstruction and apical aneurysm formation in a single family:case report[J]. Cardiovasc Ultrasound,2009,7:26.
[61]Martin S. Maron, Iacopo Olivotto, Sandro Betocchi, Susan A. Casey, John R. Lesser, Maria A. Losi, Franco Cecchi, Maron. BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy [J]. N Engl J Med, 2003,348:295-303.
[62]Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy[J]. Circulation,2008,118(15):1541-1549.
[63]Perry M. Elliott, Juan R. Gimeno, Maria T. Tome, Jaymin Shah, Deirdre Ward, Rajesh Thaman, Jens Mogensen, McKenna. WJ. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy[J]. Eur Heart J,2006,27:1933-1941.
[64]Konno T, Fujino N, Hayashi K, Uchiyama K, Masuta E, Katoh H, Sakamoto Y, Tsubokawa T, Ino H, Yamagishi M. Differences in the diagnostic value of various criteria of negative T waves for hypertrophic cardiomyopathy based on a molecular genetic diagnosis[J]. Clin Sci (Lond),2007,112(11):577-582.
[65]Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years:clinical perspectives[J]. J Am Coll Cardiol,2012,60(8): 705-715.
[66]Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy [J]. Am J Cardiol,2011,107(4):604-608.
[67]Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy[J]. Int J Cardiol, 2011,152(2):258-259.
[68]Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM. Imaging phenotype versus genotype in hypertrophic cardiomyopathy [J]. Circ Cardiovasc Imaging, 2011,4(2):156-168.
[1]Barry J. Maron, Maron MS. Hypertrophic cardiomyopathy[J]. The Lancet, 2013,381(9862):242-255.
[2]Schwartz PJ, Corrado D. Sudden Cardiac Death in Young Competitive Athletes[J]. Eur Heart J,2012,33(16):1986-1988.
[3]Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy[J]. Circulation,2010,121(3): 445-456.
[4]Ho. CY. Hypertrophic Cardiomyopathy in 2012[J]. Circulation Journal, 2012,125:1432-1438.
[5]Barry J. Maron, Julius M. Gardin, John M. Flack, Samuel S. Gidding, Tom T. Kurosaki, Bild. DE. Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults. Echocardiographic Analysis of 4111 Subjects in the CARDIA Study [J]. Circulation,1995,92:785-789.
[6]Elliott P, McKenna WJ. Hypertrophic cardiomyopathy[J]. The Lancet, 2004,363(9424):1881-1891.
[7]Maron BJ. Hypertrophic cardiomyopathy a systematic review[J]. JAMA, 2002,287(10):1308-1320.
[8]Perry M. Elliott, Jan Poloniecki, Shaughan Dickie, Sanjay Sharma, Lorenzo Monserrat, Amanda Varnava, Niall G. Mahon, McKenna WJ. Sudden death in hypertrophic cardiomyopathy:Identification of High Risk Patients[J]. J Am Coll Cardiol, 2000,36(7):2212-2218.
[9]Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy [J]. N Engl J Med,1997,336:775-785.
[10]Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death[J]. World J Cardiol,2010,2(9):289-298.
[11]Cannon RI. Assessing risk in hypertrophic cardiomyopathy[J]. N Engl J Med,2003,349:1016-1018.
[12]Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy [J]. Dtsch Arztebl Int,2011,108(13):209-215.
[13]Colan SD. Treatment of hypertrophic cardiomyopathy in childhood [J]. Progress in Pediatric Cardiology,2011,31(1):13-19.
[14]Paolo Spirito, Autore C. Management of hypertrophic cardiomyopathy [J]. BMJ,2006,332:1251-1255.
[15]Varnava AM, Elliott PM, Mahon N, Davies MJ, WJ M. Relationship between myocyte disarray and outcome in hypertrophic cardiomyopathy[J]. Am J Cardiol,2001,88:275-279.
[16]Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2008,51(14):1369-1374.
[17]Moon JC, Mogensen J, Elliott PM, Smith GC, Elkington AG, Prasad SK, Pennell DJ, McKenna WJ. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin Ⅰ[J]. Heart,2005,91(8):1036-1040.
[18]Moon JCC, McKenna WJ, McCrohon J A, Elliott PM, Smith GC, Pennell D J. Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2003,41(9):1561-1567.
[19]Deborah H. Kwon, Randolph M. Setser, Zoran B. Popovic, Maran Thamilarasan, Srikanth Sola, Paul Schoenhagen, Mario J. Garcia, Scott D. Flamm, Harry M. Lever, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study.[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[20]Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy [J]. Circ Heart Fail,2008,1(3): 184-191.
[21]Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy:correlation with histopathology and prevalence of ventricular tachycardia[J]. J Am Coll Cardiol,2009,54(3):242-249.
[22]Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2012,5(4):370-377.
[23]McNamara MT, Tscholakoff D, Revel D, Soulen R, Schechtmann N, Botvinick E, CB H. Differentiation of reversible and irreversible myocardial injury by MR imaging with and without gadolinium-DTPA[J]. Radiology,1986,158(3):765-769.
[24]Wilson JM, Villareal RP, Hariharan R, Massumi A, Muthupillai R, SD F. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy [J]. Tex Heart Inst J,2002,29:176-180.
[25]Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2004,43(12): 2260-2264.
[26]Shirani J, Pick R, Roberts WC, BJ. M. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death[J]. J Am Coll Cardiol,2000,35:36-44.
[27]Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O'rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL, Klein WW, Priori SG, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy [J]. J Am Coll Cardiol, 2003,42(9):1687-1713.
[28]Maron B. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines[J]. Eur Heart J,2003,24(21):1965-1991.
[29]Heinrich G. Klues, Andrea Schiffers, Maron. BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy:Morphologic Observations and Significance As Assessed by Two-Dimensional Echocardiography in 600 Patients[J]. J Am Coll Cardiol,1995,36:1699-1708.
[30]Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy[J]. Circulation,1978,58(3):402-408.
[31]Andrew C.Y.To, Ashwat Dhillon, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2011,4(10):1123-1137.
[32]Noureldin RA, Liu S, Nacif MS, Judge DP, Halushka MK, Abraham TP, Ho C, Bluemke DA. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2012,14:17.
[33]Morton G, Chiribiri A, Ishida M, Hussain ST, Schuster A, Indermuehle A, Perera D, Knuuti J, Baker S, Hedstrom E, Schleyer P, O'Doherty M, Barrington S, Nagel E. Quantification of absolute myocardial perfusion in patients with coronary artery disease:comparison between cardiovascular magnetic resonance and positron emission tomography[J]. J Am Coll Cardiol,2012,60(16):1546-1555.
[34]Techasith T, Cury RC. Stress myocardial CT perfusion:an update and future perspective[J]. JACC Cardiovasc Imaging,2011,4(8):905-916.
[35]Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy[J]. J Thorac Cardiovasc Surg,2011,141(2):439-443.
[36]Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy[J]. Circ Heart Fail,2010,3(1): 51-58.
[37]O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11):867-874.
[38]Musat D, Marineci S, Sherrid MV. Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy?[J]. Prog Cardiovasc Dis,2012,54(6): 535-542.
[39]Menon SC, Eidem BW, Dearani JA, Ommen SR, Ackerman MJ, Miller D. Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents[J]. J Am Soc Echocardiogr,2009,22(12): 1327-1334.
[40]Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,56(11): 875-887.
[41]Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy [J]. Heart, 2012,98(6):438-442.
[42]Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement[J]. Magn Reson Med,2002,47(2):372-383.
[43]Salerno M, Kramer CM. Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance:the future looks bright[J]. J Am Coll Cardiol,2010,56(11):888-889.
[44]Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy[J]. Am J Cardiol,2010,106(2): 261-267.
[45]Manuel D. Cerqueira, Neil J. Weissman, Vasken Dilsizian, Alice K. Jacobs, Sanjiv Kaul, Warren K. Laskey, Dudley J. Pennell, John A. Rumberger, Ryan T, Verani MS. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart:A Statement for Healthcare Professionals From the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2002,105(4):539-542.
[46]Nojiri A, Hongo K, Kawai M, Komukai K, Sakuma T, Taniguchi I, Yoshimura M. Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy [J]. J Cardiol,2011,58(3):253-260.
[47]Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, Petryka J, Dabrowski M, Kepka C, Ruzyllo W. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy[J]. Eur J Radiol,2010,74(3):149-153.
[48]Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance[J]. JACC Cardiovasc Imaging, 2011,4(2):150-156.
[49]Buechel EV, Kaiser T, Jackson C, Schmitz A, Kellenberger CJ. Normal right-and left ventricular volumes and myocardial mass in children measured by steady state free precession cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson, 2009,11:19.
[50]Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M, Quarta G, Nistri S, Cecchi F, Salton CJ, Udelson JE, Manning WJ, Maron BJ. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2008,52(7):559-566.
[51]Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, MY. D. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation[J]. J Thorac Cardiovasc Surg,2010,140(2):317-324.
[52]Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, Garcia MJ, Flamm SD, Lever HM, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study [J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[53]Ismail TF, Jabbour A, Mallorie A, Cowling T, Das B, Gulati A, Wage R, Pennell D, Prasad S. Role of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in the Risk Stratification of Hypertrophic Cardiomyopathy [J]. J Am Coll Cardiol,2012,59(13):E1581.
[54]Moon J, Cho IJ, Shim CY, Ha J-W, Jang Y, Chung N, Rim S-J. Abnormal Myocardial Capillary Density in Apical Hypertrophic Cardiomyopathy Can Be Assessed by Myocardial Contrast Echocardiography[J]. Circulation Journal,2010,74(10): 2166-2172.
[55]Ho KT, Chua KC, Klotz E, Panknin C. Stress and rest dynamic myocardial perfusion imaging by evaluation of complete time-attenuation curves with dual-source CT[J]. JACC Cardiovasc Imaging,2010,3(8):811-820.
[56]Munenobu Motoyasu, Kurita T, Katsuya Onishi, Shoko Uemura, Takashi Tanigawa, Tsutomu Okinaka, Kan Takeda, Takeshi Nakano, Masaaki Ito, Sakuma. H. Correlation Between Late Gadolinium Enhancement and Diastolic Function in Hypertrophic Cardiomyopathy Assessed by Magnetic Resonance Imaging[J]. Circ J, 2008,72:378-383.
[57]Giancarlo Todiere, Giovanni Donato Aquaro, Paolo Piaggi, Formisano F, Andrea Barison, Pier Giorgio Masci, Elisabetta Strata, Lorenzo Bacigalupo, Mario Marzilli, Alessandro Pingitore, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2012,60(10):922-929.
[58]Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy [J]. Eur Heart J,2009,30(16):2003-2010.
[59]Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy [J]. Hum Pathol,2013,44(1):133-141.
[60]Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2005,45(5):697-704.
[61]乔树宾.肥厚性心肌病-基础与临床[M].人民卫生出版社,2012.
[62]Sorajja P, Allison T, Hayes C, Nishimura RA, Lam CS, Ommen SR. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy [J]. Am J Cardiol,2012,109(10):1494-1498.
[63]Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy[J]. JACC Cardiovasc Imaging,2012,5(1):119-122.
[64]Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy [J]. Am J Cardiol,2011,107(4):604-608.
[65]Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy [J]. Int J Cardiol, 2011,152(2):258-259.
[66]Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM. Imaging phenotype versus genotype in hypertrophic cardiomyopathy[J]. Circ Cardiovasc Imaging, 2011,4(2):156-168.
[67]Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years:clinical perspectives [J]. J Am Coll Cardiol,2012,60(8): 705-715.
[1]Barry J. Maron, Maron MS. Hypertrophic cardiomyopathy[J]. The Lancet, 2013,381(9862):242-255.
[2]Noureldin RA, Liu S, Nacif MS, Judge DP, Halushka MK, Abraham TP, Ho C, Bluemke DA. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2012,14:17.
[3]Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy [J]. Circulation,1978,58(3):402-408.
[4]E, B, Lambrew CT, Rockoff SD, Ross J Jr, AG M. Idiopathic hypertrophic subaortic stenosis, I:a description of the disease based upon an analysis of 64 patients[J]. Circulation,1964,30:3-119.
[5]Wigle ED, Rakowski H, Kimball BP, WG. W. Hypertrophic cardiomyopathy: clinical spectrum and treatment[J]. Circulation,1995,92:1680-1692.
[6]Maron BJ. Hypertrophic cardiomyopathy an important global disease[J]. Am J Med,2004,116:63-66.
[7]Maron BJ. Hypertrophic cardiomyopathy a systematic review[J]. JAMA, 2002,287(10):1308-1320.
[8]Alcalai R, Seidman JG, CE S. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics[J]. J Cardiovasc Electrophysiol,2008,19:104-110.
[9]Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy:a personal history[J]. Circ Res,2011,108(6):743-750.
[10]Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy [J]. Circulation,2010,121(3): 445-456.
[11]Christph A. Nienaber, Sabine Hiller, Spielmann RP, Manfred Geriger, Kuck K-H. Syncope in hypertrophic cardiomyopathy Multivariate analysis of prognostic determinants[J].1990.
[12]Perry M. Elliott, Jan Poloniecki, Shaughan Dickie, Sanjay Sharma, Lorenzo Monserrat, Amanda Varnava, Niall G. Mahon, McKenna WJ. Sudden death in hypertrophic cardiomyopathy:Identification of High Risk Patients[J]. J Am Coll Cardiol, 2000,36(7):2212-2218.
[13]Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death[J]. World J Cardiol,2010,2(9):289-298.
[14]Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, Nakajima T, Kawashiro N, Kawana M, Hagiwara N. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2011,57(23):2346-2355.
[15]Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, Abe Y, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy[J]. Magn Reson Imaging,2004,22(2):155-161.
[16]Kunihiko Teraoka, Masaharu Hirano, Ookubo H, Kazuyoshi Sasaki, Hiroaki Katsuyama, Masayuki Amino, Yimihiko Abe, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy [J]. Magn Reson Imaging, 2005,23(5):701.
[17]Prinz C, Schwarz M, Ilic I, Laser KT, Lehmann R, Prinz EM, Bitter T, Vogt J, van Buuren F, Bogunovic N, Horstkotte D, Faber L. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy[J]. Can J Cardiol,2013,29(3):358-363.
[18]Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy[J]. Hum Pathol,2013,44(1):133-141.
[19]Giancarlo Todiere, Giovanni Donato Aquaro, Paolo Piaggi, Formisano F, Andrea Barison, Pier Giorgio Masci, Elisabetta Strata, Lorenzo Bacigalupo, Mario Marzilli, Alessandro Pingitore, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2012,60(10):922-929.
[20]Todiere G, Aquaro G, Pingitore A, Barison A, Strata E, Capozza P, Lombardi M. Progression of myocardial fibrosis and functional clinical status in Hypertrophic Cardiomyopathy:a study with cardiac magnetic resonance[J]. Journal of Cardiovascular Magnetic Resonance,2011,13(Suppl 1):P272.
[21]Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy[J]. Dtsch Arztebl Int,2011,108(13):209-215.
[22]Ho. CY. Hypertrophic Cardiomyopathy in 2012[J]. Circulation Journal, 2012,125:1432-1438.
[23]Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2009,54(3):220-228.
[24]Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy:from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2009,54(3):191-200.
[25]Michael J. Ackerman, Sara L. VanDriest, Steve R. Ommen, Melissa L. Will, Rick A. Nishimura, A. Jamil Tajik, J. B, Gersh BJ. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy a comprehensive outpatient perspective [J]. J Am Coll Cardiol,2002,39(12):2042-2048.
[26]Niimura H BL, Sangwatanaroj S. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy[J]. N Engl J Med,1998,338:1248-1257.
[27]Van Driest SL, Ackerman MJ, SR O. Prevalence and severity of benign mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy [J]. Circulation,2002,106:3085-3090.
[28]Landstrom AP, MJ A. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy [J]. Circulation,2010,122:2441-2449.
[29]BJ Maron, SA Bodison, YE Wesley, E Tucker, Green. K. Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease[J]. J Am Coll Cardiol,1987,10(6):1214-1221.
[30]Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years:clinical perspectives [J]. J Am Coll Cardiol,2012,60(8): 705-715.
[31]Dadlani GH, Harmon WG, Perez-Colon E, Sokoloski MC, Wilmot I, Lipshultz SE. Diagnosis and screening of hypertrophic cardiomyopathy in childrenfJ]. Progress in Pediatric Cardiology,2011,31(1):21-27.
[32]Colan SD. Hypertrophic cardiomyopathy in childhood[J]. Heart Fail Clin, 2010,6(4):433-444, vii-iii.
[33]Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2012,5(4):370-377.
[34]Schwartz PJ, Corrado D. Sudden Cardiac Death in Young Competitive Athletes[J]. Eur Heart J,2012,33(16):1986-1988.
[35]Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G.2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2011,58(25):e212-260.
[36]Colan SD. Treatment of hypertrophic cardiomyopathy in childhood[J]. Progress in Pediatric Cardiology,2011,31(1):13-19.
[37]Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia[J]. J Am Coll Cardiol,2012,60(20):1993-2004.
[38]Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy [J]. Heart, 2012,98(6):438-442.
[39]Shirley KW, Adirim TA. Sudden Cardiac Death in Young Athletes[J]. Clinical Pediatric Emergency Medicine,2005,6(4):194-199.
[40]Perry M. Elliott, Juan R. Gimeno, Maria T. Tome, Jaymin Shah, Deirdre Ward, Rajesh Thaman, Jens Mogensen, McKenna. WJ. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy [J]. Eur Heart J,2006,27:1933-1941.
[41]M Li, QB Wang, Cheng k. Long term follow-up results of 199 patients with hypertrophic cardiomyopathy [J]. Zhonghua Xin Xue Guan Bing Za Zhi,2007,35(11): 988-991.
[42]F Cecchi, A Sgalambro, M Baldi, B Sotgia, D Antoniucci, PG Camici, R Sciagra, Olivotto. I. Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy[J]. J Cardiovasc Transl Res, 2009,2(4):452-461.
[43]Jahnke C, Furundzija V, Gebker R, Manka R, Frick M, Schnackenburg B, Marx N, Paetsch I. Gender-based prognostic value of pharmacological cardiac magnetic resonance stress testing:head-to-head comparison of adenosine perfusion and dobutamine wall motion imaging[J]. Int J Cardiovasc Imaging,2012,28(5):1087-1098.
[44]Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, Schoenberg SO, Sueselbeck T, Germans T, Streitner F, Borggrefe M, Papavassiliu T. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy [J]. J Cardiovasc Magn Reson,2010,12:30.
[45]Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2008,51(14):1369-1374.
[46]Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, Conte MR, Casazza F, Galderisi M, Maron BJ, Cecchi F. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy)[J]. Am J Cardiol,2006,98(7):960-965.
[47]Anwar AM, Soliman OI, Nemes A, Geleijnse ML, ten Cate FJ. An integrated approach to determine left atrial volume, mass and function in hypertrophic cardiomyopathy by two-dimensional echocardiography[J]. Int J Cardiovasc Imaging, 2008,24(1):45-52.
[48]Papavassiliu T, Germans T, Fluchter S, Doesch C, Suriyakamar A, Haghi D, Suselbeck T, Wolpert C, Dinter D, Schoenberg SO, van Rossum AC, Borggrefe M. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation[J]. J Cardiovasc Magn Reson,2009,11:34.
[49]Cecchi F. Does LV outflow tract obstruction increase the risk of sudden death in hypertrophic cardiomyopathy?[J]. Nat Clin Pract Cardiovasc Med,2007,4(4): 194-195.
[50]Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D, ten Cate FJ. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations[J]. JACC Cardiovasc Imaging,2009,2(1):58-64.
[51]Menon SC, Eidem BW, Dearani JA, Ommen SR, Ackerman MJ, Miller D. Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents [J]. J Am Soc Echocardiogr,2009,22(12): 1327-1334.
[52]Alia V, Koneru S, Reddy M, Fernandes J, Lakkireddy D, Hunter C, Mooss A. Delayed Contrast Enhancement on Cardiac Mri and Risk of Clinically Significant Ventricular Arrhythmias in Hypertrophic Cardiomyopathy:A Meta-Analysis of Observational Studies[J]. J Am Coll Cardiol,2012,59(13):E1226.
[53]赵世华.心血管病磁共振诊断学[M].人民军医出版社,2011.
[54]Uretsky S. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy [J]. Prog Cardiovasc Dis,2012,54(6):512-516.
[55]Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy [J]. Am J Cardiol,2011,107(4):604-608.
[56]Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy [J]. Circulation,2005,112(6):855-861.
[57]Moon JCC. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography[J]. Heart,2004,90(6):645-649.
[58]Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy [J]. Circulation,2008,118(15):1541-1549.
[59]Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart A, Council on Clinical Cardiology HF, Transplantation C, Quality of C, Outcomes R, Functional G, Translational Biology Interdisciplinary Working G, Council on E, Prevention. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[60]Rose A. Evaluation of pathological criteria for diagnosis of hypertrophic cardiomyopathy [J]. Histopathology,1984,8(3):395-406.
[61]MJ Davies, McKenna W. Hypertrophic cardiomyopathy--athology and pathogenesis[J]. Histopathology,1995,26(6):493-500.
[62]Turer AT, Samad Z, Valente AM, Parker MA, Hayes B, Kim RJ, Kisslo J, Wang A. Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy [J]. Eur J Echocardiogr,2011,12(2):131-139.
[63]Factor S, J Butany, MJ Sole, ED Wigle, WC Williams, Rojkind. M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,1991,17(6):1343-1351.
[64]Hughes SE. The pathology of hypertrophic cardiomyopathy [J]. Histopathology,2004,44:412-427.
[65]A. Ellims, L. lles, L. Ling, J. Hare, D. Kaye, Taylor A. Diffuse Myocardial Fibrosis in Hypertrophic Cardiomyopathy Identified by Cardiac Magnetic Resonance Imaging is Associated with Left Ventricular Diastolic Dysfunction[J]. Heart, Lung and Circulation,2012.
[66]E. Jacksona, N. Bellengerb, M. Seddonb, S. Hardena, Peebles C. Ischaemic and non-ischaemic cardiomyopathies-cardiac MRI appearances with delayed enhancement[J]. Clin Radiol,2007,62(5):395-403.
[67]Rehwald WG. Myocardial Magnetic Resonance Imaging Contrast Agent Concentrations After Reversible and Irreversible Ischemic Injury[J]. Circulation, 2002,105(2):224-229.
[68]Hanns-Joachim Weinmann, Robert C. Brasch, Wolf-R. Press, Wesbey. GE. Characteristics of gadolinium-DTPA complex a potential NMR contrast agent[J]. Am J Roentgenol,1984,142:619-624.
[69]Kim RJ, Judd RM, Chen EL, Fieno DS, Parrish TB, Lima JAC. Relationship of Elevated 23Na Magnetic Resonance Image Intensity to Infarct Size After Acute Reperfused Myocardial Infarction[J]. Circulation,1999,100(2):185-192.
[70]Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement[J]. Magn Reson Med,2002,47(2):372-383.
[71]Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy:correlation with histopathology and prevalence of ventricular tachycardia[J]. J Am Coll Cardiol,2009,54(3):242-249.
[72]Huang L, Han R, Ai T, Sun Z, Bai Y, Cao Z, Morelli JN, Xia L. Assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy:First-pass myocardial perfusion cardiovascular magnetic resonance imaging at 1.5 T[J]. Clin Radiol, 2013.
[73]Jordan N Andrew, Lyne Jonathan, Tom W. Unusual scarring patterns on cardiac magnetic resonance imaging-A potentially treatable etiology not to be missed[J]. Can J Cardiol,2010,26(4):el49-150.
[74]Lubna Choudhury, Heiko Mahrholdt, Anja Wagner, Kelly M. Choi, Michael D. Elliott, Francis J. Klocke, Robert O. Bonow, Robert M. Judd, Kim. RJ. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2002,40:2156-2164.
[75]Hiroshi Satoh, Fumitaka Matoh, Katsunori Shiraki, Takeji Saitoh, Keiichi Odagiri, Masao Saotome, Tsuyoshi Urushida, Hideki Katoh, Yasuo Takehara, Harumi Sakahara, Hayashi. H. Delayed enhancement on cardiac magnetic resonance and clinical, morphological, and electrocardiographical features in hypertrophic cardiomyopathy [J]. J Card Fail,2009,15(5):419-427.
[76]Moon JCC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2003,41(9):1561-1567.
[77]Moon JC. What Is Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy?[J]. Revista Espanola de Cardiologia (English Edition),2007,60(1): 1-4.
[78]Moon JCC. Reed E. Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2004,43(12): 2260-2264.
[79]Caitlin J. Harrigan, Evan Appelbaum, Barry J. Maron, Jacqueline L. Buros, C. Michael Gibson, John R. Lesser, James E. Udelson, Warren J. Manning, Maron MS. Significance of Papillary Muscle Abnormalities Identified by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy [J]. Am J Cardiol,2008,101(5):668-673.
[80]Kwon DH, Setser RM, Thamilarasan M, Popovic ZV, Smedira NG, Schoenhagen P, Garcia MJ, Lever HM, MY D. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. Heart,2007,94(10):1295-1301.
[81]Kwon DH, Smedira NG, Thamilarasan M, Lytle BW. Lever H, MY. D. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation[J]. J Thorac Cardiovasc Surg,2010,140(2):317-324.
[82]Andrew C.Y.To, Ashwat Dhillon, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2011,4(10):1123-1137.
[83]Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW.2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:Executive Summary[J]. J Am Coll Cardiol,2011,58(25): 2703-2738.
[84]Hwang HJ, Choi EY, Kwan J, Kim SA, Shim CY, Ha JW, Rim SJ, Chung N, Kim SS. Dynamic change of mitral apparatus as potential cause of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. Eur J Echocardiogr, 2011,12(1):19-25.
[85]White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, Leong-Sit P, Warren H, Thompson T, Drangova M, Krahn A. Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhythmias[J]. Circ Cardiovasc Imaging,2012,5(1):12-20.
[86]Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy[J]. JACC Cardiovasc Imaging,2012,5(1):119-122.
[87]Ismail TF, Jabbour A, Mallorie A, Cowling T, Das B, Gulati A, Wage R, Pennell D, Prasad S. Role of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in the Risk Stratification of Hypertrophic Cardiomyopathy[J]. J Am Coll Cardiol,2012,59(13):E1581.
[88]Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, Garcia MJ, Flamm SD, Lever HM, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[89]Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy[J]. Circ Heart Fail,2008,1(3): 184-191.
[90]O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,56(11):867-874.
[91]Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11): 875-887.
[92]Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy [J]. Circ Heart Fail,2010,3(1): 51-58.
[93]Barry J. Maron, Julius M. Gardin, John M. Flack, Samuel S. Gidding, Tom T. Kurosaki, Bild. DE. Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults. Echocardiographic Analysis of 4111 Subjects in the CARDIA Study[J]. Circulation,1995,92:785-789.
[94]Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms[J]. J Am Coll Cardiol,2005,45(7):1076-1080.
[95]Bunch TJ, Chandrasekaran K, Ehrsam JE, Hammill SC, Urban LH, Hodge DO, Ommen SR, Pellikka PA. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy [J]. Am J Cardiol, 2007,99(6):835-838.
[96]Deborah H. Kwon, Randolph M. Setser, Zoran B. Popovic, Maran Thamilarasan, Srikanth Sola, Paul Schoenhagen, Mario J. Garcia, Scott D. Flamm, Harry M. Lever, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study.[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[97]Nazarian S, Lima JA. Cardiovascular magnetic resonance for risk stratification of arrhythmia in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2008,51(14):1375-1376.
[98]Munenobu Motoyasu, Kurita T, Katsuya Onishi, Shoko Uemura, Takashi Tanigawa, Tsutomu Okinaka, Kan Takeda, Takeshi Nakano, Masaaki Ito, Sakuma. H. Correlation Between Late Gadolinium Enhancement and Diastolic Function in Hypertrophic Cardiomyopathy Assessed by Magnetic Resonance Imaging[J]. Circ J, 2008,72:378-383.
[99]Wayne J. S t, Trohman. RG, Martin Bilsker, Liaqat Zaman, Agustin Castellanos, Myerburg. RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,1986,7(3):701-704.
[100]Pujadas S, Vidal-Perez R, Hidalgo A, Leta R, Carreras F. Barros A, Bayes-Genis A, Subirana MT, Pons-Llado G. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy:a cardiac magnetic resonance imaging study [J]. Eur J Radiol,2010,75(2):88-91.
[101]乔树宾.肥厚性心肌病-基础与临床[M].人民卫生出版社,2012.
[102]Tani T, Yagi T, Kitai T, Kim K, Nakamura H, Konda T, Fujii Y, Kawai J, Kobori A, Ehara N, Kinoshita M, Kaji S, Yamamuro A, Morioka S, Kita T, Furukawa Y. Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy [J]. Cardiovasc Ultrasound,2011,9:34.
[103]Losi MA, Betocchi S, Barbati G, Parisi V, Tocchetti CG, Pastore F, Migliore T, Contaldi C, Caputi A, Romano R, Chiariello M. Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy [J]. J Am Soc Echocardiogr,2009,22(1):76-81.
[104]Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy [J]. Heart,2006,92(9):1339-1344.
[105]Jensen MK, Havndrup O, Hassager C, Helqvist S, Kelbaek H, Jorgensen E, Kober L, Bundgaard H. Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy [J]. Scand Cardiovasc J,2011,45(3):153-160.
[106]Butz T, Horstkotte D, Koerfer J, Langer C, Seggewiss H, Faber L, Assessment of myocardial scarring by contrast enhanced magnetic resonance imaging in a patient 11 years after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy [J]. Int J Cardiol,2010,145(1):e3-5.
[107]Chen S, Yuan J, Zhang J, Qiao S, Duan F, Lv X, Hu F, Yang W, Yang Y. Assessment of atrial conduction abnormalities in patients with hypertrophic cardiomyopathy before and one year after alcohol septal ablation[J]. Cardiology, 2012,123(4):254-260.
[108]Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, Hansen TF, Kober L, Endresen K, Eriksson MJ, Jorgensen E, Amlie JP, Gadler F, Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy:a Scandinavian multicenter study[J]. Circ Cardiovasc Interv,2011,4(3):256-265.
[109]Vogel-Claussen J, Santaularia Tomas M, Newatia A, Boyce D, Pinheiro A, Abraham R, Abraham T, Bluemke DA. Cardiac MRI evaluation of hypertrophic cardiomyopathy:left ventricular outflow tract/aortic valve diameter ratio predicts severity of LVOT obstruction[J]. J Magn Reson Imaging,2012,36(3):598-603.
[110]Fukuda S, Lever HM, Stewart WJ, Tran H, Song JM, Shin MS, Greenberg NL, Wada N, Matsumura Y, Toyono M, Smedira NG, Thomas JD, Shiota T. Diagnostic value of left ventricular outflow area in patients with hypertrophic cardiomyopathy:a real-time three-dimensional echocardiographic study[J]. J Am Soc Echocardiogr, 2008,21(7):789-795.
[111]Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,55(8):823-834.
[112]Marin F, Gimeno JR, Paya E, Garcia-Alberola A, Perez-Alvarez L Fernandez X, de la Morena G, Sogorb F, Castro-Beiras A, Valdes M, Martinez JG, Monserrat L. Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers [J]. Revista Espanola de Cardiologia (English Edition), 2006,59(6):537-544.
[113]Martin ET, Coman JA, Shellock FG, Pulling CC, Fair R, Jenkins K. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla[J]. J Am Coll Cardiol,2004,43(7):1315-1324.
[114]Nazarian S, Roguin A, Zviman MM, Lardo AC, Dickfeld TL, Calkins H, Weiss RG, Berger RD, Bluemke DA, Halperin HR. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla[J]. Circulation,2006,114(12):1277-1284.
[115]Roguin A, Zviman MM, GR M. Modern pacemaker and implantable cardioverter defibrillator systems can be magnetic resonance imaging safe in vitro and in vivo assessment of safety and function at 1.5 T[J]. Circulation,2004,110(475-482).
[116]Sommer T, Naehle CP, A Y. Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients:a prospective study with 115 examinations[J]. Circulation,2006,114:1285-1292.
[117]Russo RJ, Costa H, Kabra A, Doud D, Uretsky S, Wolff S, Martin E, Machado C, Higgins S, Tominaga G, Florin T, Bloomgarden D, Birgersdotter-Green U, Ponce G, Schaerf R, Lampert R, Shah D, Arshad A, Anderson J, Tonkin A, Rivard A, Fyke F, Biederman R. Determining the Risks of Magnetic Resonance Imaging at 1.5 Tesla for Patients with Pacemakers and Implantable Cardioverter Defibrillators:The Magnasafe Registry[J]. J Am Coll Cardiol,2013,61(10):E810.
[118]Cohen JD, Costa HS, Russo RJ. Determining the risks of magnetic resonance imaging at 1.5 tesla for patients with pacemakers and implantable cardioverter defibrillators[J]. Am J Cardiol,2012,110(11):1631-1636.
[119]Dhandapany P, Sadayappan S, Xue Y, Powell G, Rani D, Nallari P, Rai T, Khullar M, Soares P, Bahl A. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia[J]. Nat Genet,2009,41:187-191.
[120]Girolami F, Ho C, Semsarian C, Baldi M, Will M, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman M, Olivotto I. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations [J]. J Am Coll Cardiol,2010,55:1444-1453.
[121]Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, Nistri S, Sgalambro A, Grifoni C, Torricelli F, Camici PG, Cecchi F. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations [J]. J Am Coll Cardiol,2011,58(8):839-848.
[122]Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy[J]. Int J Cardiol, 2011,152(2):258-259.
[123]Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM. Imaging phenotype versus genotype in hypertrophic cardiomyopathy[J]. Circ Cardiovasc Imaging, 2011,4(2):156-168.
[124]Morita H, Nagai R, Seidman JG, Seidman CE. Sarcomere gene mutations in hypertrophy and heart failure[J]. J Cardiovasc Transl Res,2010,3(4):297-303.
[125]Hershberger RE. A glimpse into multigene rare variant genetics:triple mutations in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,55(14): 1454-1455.
[2]Schwartz PJ, Corrado D. Sudden Cardiac Death in Young Competitive Athletes[J]. Eur Heart J,2012,33(16):1986-1988.
[3]Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy[J]. Circulation,2010,121(3): 445-456.
[4]Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, Nakajima T, Kawashiro N, Kawana M, Hagiwara N. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2011,57(23):2346-2355.
[5]Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death[J]. World J Cardiol,2010,2(9):289-298.
[6]Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, Abe Y, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy [J]. Magn Reson Imaging,2004,22(2):155-161.
[7]Kunihiko Teraoka, Masaharu Hirano, Ookubo H, Kazuyoshi Sasaki, Hiroaki Katsuyama, Masayuki Amino, Yimihiko Abe, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy [J]. Magn Reson Imaging, 2005,23(5):701.
[8]Prinz C, Schwarz M,Ilie I, Laser KT, Lehmann R, Prinz EM, Bitter T, Vogt J, van Buuren F, Bogunovic N, Horstkotte D, Faber L. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy[J]. Can J Cardiol,2013,29(3):358-363.
[9]Noureldin RA, Liu S, Nacif MS, Judge DP, Halushka MK, Abraham TP, Ho C, Bluemke DA. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2012,14:17.
[10]Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy [J]. Hum Pathol,2013,44(1):133-141.
[11]Giancarlo Todiere, Giovanni Donato Aquaro, Paolo Piaggi, Formisano F, Andrea Barison, Pier Giorgio Masci, Elisabetta Strata, Lorenzo Bacigalupo, Mario Marzilli, Alessandro Pingitore, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2012,60(10):922-929.
[12]Todiere G, Aquaro G, Pingitore A, Barison A, Strata E, Capozza P, Lombardi M. Progression of myocardial fibrosis and functional clinical status in Hypertrophic Cardiomyopathy:a study with cardiac magnetic resonance[J]. Journal of Cardiovascular Magnetic Resonance,2011,13(Suppl 1):P272.
[13]Ho. CY. Hypertrophic Cardiomyopathy in 2012[J]. Circulation Journal, 2012,125:1432-1438.
[14]Uretsky S. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy [J]. Prog Cardiovasc Dis,2012,54(6):512-516.
[15]Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy:correlation with histopathology and prevalence of ventricular tachycardia[J]. J Am Coll Cardiol,2009,54(3):242-249.
[16]White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, Leong-Sit P, Warren H, Thompson T, Drangova M, Krahn A. Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhythmias[J]. Circ Cardiovasc Imaging,2012,5(1):12-20.
[17]Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2012,5(1):119-122.
[18]Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy [J]. Heart, 2012,98(6):438-442.
[19]Ismail TF, Jabbour A, Mallorie A, Cowling T, Das B, Gulati A, Wage R, Pennell D, Prasad S. Role of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in the Risk Stratification of Hypertrophic Cardiomyopathy [J]. J Am Coll Cardiol,2012,59(13):E1581.
[20]Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2008,51(14):1369-1374.
[21]Bunch TJ, Chandrasekaran K, Ehrsam JE, Hammill SC, Urban LH, Hodge DO, Ommen SR, Pellikka PA. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy[J]. Am J Cardiol, 2007,99(6):835-838.
[22]Deborah H. Kwon, Randolph M. Setser, Zoran B. Popovic, Maran Thamilarasan, Srikanth Sola, Paul Schoenhagen, Mario J. Garcia, Scott D. Flamm, Harry M. Lever, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study.[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[23]Nazarian S, Lima JA. Cardiovascular magnetic resonance for risk stratification of arrhythmia in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2008,51(14):1375-1376.
[24]Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy[J]. Circ Heart Fail,2008,1(3): 184-191.
[25]Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,56(11): 875-887.
[26]Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy[J]. Circ Heart Fail,2010,3(1): 51-58.
[27]Strijack B, Ariyarajah V, Soni R, Jassal DS, Greenberg CR, McGregor R, Morris A. Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype[J]. J Cardiovasc Magn Reson,2008,10:58.
[28]Heinrich G. Klues, Andrea Schiffers, Maron. BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy:Morphologic Observations and Significance As Assessed by Two-Dimensional Echocardiography in 600 Patients[J]. J Am Coll Cardiol,1995,36:1699-1708.
[29]Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy [J]. Circulation,1978,58(3):402-408.
[30]Rose A. Evaluation of pathological criteria for diagnosis of hypertrophic cardiomyopathy[J]. Histopathology,1984,8(3):395-406.
[31]Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart A, Council on Clinical Cardiology HF, Transplantation C, Quality of C, Outcomes R, Functional G, Translational Biology Interdisciplinary Working G, Council on E, Prevention. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[32]Andrew C.Y.To, Ashwat Dhillon, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2011,4(10):1123-1137.
[33]Morton G, Chiribiri A, Ishida M, Hussain ST, Schuster A, Indermuehle A, Perera D, Knuuti J, Baker S, Hedstrom E, Schleyer P, O'Doherty M, Barrington S, Nagel E. Quantification of absolute myocardial perfusion in patients with coronary artery disease:comparison between cardiovascular magnetic resonance and positron emission tomography [J]. J Am Coll Cardiol,2012,60(16):1546-1555.
[34]Techasith T, Cury RC. Stress myocardial CT perfusion:an update and future perspective[J]. JACC Cardiovasc Imaging,2011,4(8):905-916.
[35]Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy[J]. J Thorac Cardiovasc Surg,2011,141(2):439-443.
[36]Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2005,45(5):697-704.
[37]Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia[J]. J Am Coll Cardiol,2012,60(20):1993-2004.
[38]Di Salvo G, Pacileo G, Limongelli G, Baldini L, Rea A, Verrengia M, D'Andrea A, Russo MG, Calabro R. Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters[J]. J Am Soc Echocardiogr,2010,23(6):581-590.
[39]Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement[J]. Magn Reson Med,2002,47(2):372-383.
[40]Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy [J]. Dtsch Arztebl Int,2011,108(13):209-215.
[41]Salerno M, Kramer CM. Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance:the future looks bright[J]. J Am Coll Cardiol,2010,56(11):888-889.
[42]Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. Am J Cardiol,2010,106(2): 261-267.
[43]Manuel D. Cerqueira, Neil J. Weissman, Vasken Dilsizian, Alice K. Jacobs, Sanjiv Kaul, Warren K. Laskey, Dudley J. Pennell, John A. Rumberger, Ryan T, Verani MS. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart:A Statement for Healthcare Professionals From the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2002,105(4):539-542.
[44]Nojiri A, Hongo K, Kawai M, Komukai K, Sakuma T, Taniguchi I, Yoshimura M. Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy [J]. J Cardiol,2011,58(3):253-260.
[45]Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2004,43(12): 2260-2264.
[46]Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, Petryka J, Dabrowski M, Kepka C, Ruzyllo W. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy[J]. Eur J Radiol,2010,74(3):149-153.
[47]Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance[J]. JACC Cardiovasc Imaging, 2011,4(2):150-156.
[48]Buechel EV, Kaiser T, Jackson C, Schmitz A, Kellenberger CJ. Normal right- and left ventricular volumes and myocardial mass in children measured by steady state free precession cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson, 2009,11:19.
[49]O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11):867-874.
[50]Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy[J]. Eur Heart J,2009,30(16):2003-2010.
[51]Dumont CA, Monserrat L, Soler R, Rodriguez E, Fernandez X, Peteiro J, Bouzas A, Bouzas B, Castro-Beiras A. Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance[J]. Eur Heart J,2006,27(14):1725-1731.
[52]Matsubara K, Nakamura T, Kuribayashi T, Azuma A, Nakagawa M. Sustained cavity obliteration and apical aneurysm formation in apical hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2003,42(2):288-295.
[53]Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, Schoenberg SO, Sueselbeck T, Germans T, Streitner F, Borggrefe M, Papavassiliu T. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy [J]. J Cardiovasc Magn Reson,2010,12:30.
[54]Tani T, Yagi T, Kitai T, Kim K, Nakamura H, Konda T, Fujii Y, Kawai J, Kobori A, Ehara N, Kinoshita M, Kaji S, Yamamuro A, Morioka S, Kita T, Furukawa Y. Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy [J]. Cardiovasc Ultrasound,2011,9:34.
[55]Pujadas S, Vidal-Perez R, Hidalgo A, Leta R, Carreras F, Barros A, Bayes-Genis A, Subirana MT, Pons-Llado G. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy:a cardiac magnetic resonance imaging study[J]. Eur J Radiol,2010,75(2):88-91.
[56]Papavassiliu T, Germans T, Fluchter S, Doesch C, Suriyakamar A, Haghi D, Suselbeck T, Wolpert C, Dinter D, Schoenberg SO, van Rossum AC, Borggrefe M. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation[J]. J Cardiovasc Magn Reson,2009,11:34.
[57]Sorajja P, Nishimura RA, Gersh BJ, Dearani JA, Hodge DO, Wiste HJ, Ommen SR. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy:a long-term follow-up study[J]. J Am Coll Cardiol,2009,54(3): 234-241.
[58]Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2009,54(3):220-228.
[59]Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy:from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2009,54(3):191-200.
[60]Efthimiadis GK, Pliakos C, Pagourelias ED, Parcharidou DG, Spanos G, Paraskevaidis S, Styliadis IH, Parcharidis G. Hypertrophic cardiomyopathy with midventricular obstruction and apical aneurysm formation in a single family:case report[J]. Cardiovasc Ultrasound,2009,7:26.
[61]Martin S. Maron, Iacopo Olivotto, Sandro Betocchi, Susan A. Casey, John R. Lesser, Maria A. Losi, Franco Cecchi, Maron. BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy [J]. N Engl J Med, 2003,348:295-303.
[62]Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy[J]. Circulation,2008,118(15):1541-1549.
[63]Perry M. Elliott, Juan R. Gimeno, Maria T. Tome, Jaymin Shah, Deirdre Ward, Rajesh Thaman, Jens Mogensen, McKenna. WJ. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy[J]. Eur Heart J,2006,27:1933-1941.
[64]Konno T, Fujino N, Hayashi K, Uchiyama K, Masuta E, Katoh H, Sakamoto Y, Tsubokawa T, Ino H, Yamagishi M. Differences in the diagnostic value of various criteria of negative T waves for hypertrophic cardiomyopathy based on a molecular genetic diagnosis[J]. Clin Sci (Lond),2007,112(11):577-582.
[65]Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years:clinical perspectives[J]. J Am Coll Cardiol,2012,60(8): 705-715.
[66]Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy [J]. Am J Cardiol,2011,107(4):604-608.
[67]Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy[J]. Int J Cardiol, 2011,152(2):258-259.
[68]Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM. Imaging phenotype versus genotype in hypertrophic cardiomyopathy [J]. Circ Cardiovasc Imaging, 2011,4(2):156-168.
[1]Barry J. Maron, Maron MS. Hypertrophic cardiomyopathy[J]. The Lancet, 2013,381(9862):242-255.
[2]Schwartz PJ, Corrado D. Sudden Cardiac Death in Young Competitive Athletes[J]. Eur Heart J,2012,33(16):1986-1988.
[3]Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy[J]. Circulation,2010,121(3): 445-456.
[4]Ho. CY. Hypertrophic Cardiomyopathy in 2012[J]. Circulation Journal, 2012,125:1432-1438.
[5]Barry J. Maron, Julius M. Gardin, John M. Flack, Samuel S. Gidding, Tom T. Kurosaki, Bild. DE. Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults. Echocardiographic Analysis of 4111 Subjects in the CARDIA Study [J]. Circulation,1995,92:785-789.
[6]Elliott P, McKenna WJ. Hypertrophic cardiomyopathy[J]. The Lancet, 2004,363(9424):1881-1891.
[7]Maron BJ. Hypertrophic cardiomyopathy a systematic review[J]. JAMA, 2002,287(10):1308-1320.
[8]Perry M. Elliott, Jan Poloniecki, Shaughan Dickie, Sanjay Sharma, Lorenzo Monserrat, Amanda Varnava, Niall G. Mahon, McKenna WJ. Sudden death in hypertrophic cardiomyopathy:Identification of High Risk Patients[J]. J Am Coll Cardiol, 2000,36(7):2212-2218.
[9]Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy [J]. N Engl J Med,1997,336:775-785.
[10]Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death[J]. World J Cardiol,2010,2(9):289-298.
[11]Cannon RI. Assessing risk in hypertrophic cardiomyopathy[J]. N Engl J Med,2003,349:1016-1018.
[12]Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy [J]. Dtsch Arztebl Int,2011,108(13):209-215.
[13]Colan SD. Treatment of hypertrophic cardiomyopathy in childhood [J]. Progress in Pediatric Cardiology,2011,31(1):13-19.
[14]Paolo Spirito, Autore C. Management of hypertrophic cardiomyopathy [J]. BMJ,2006,332:1251-1255.
[15]Varnava AM, Elliott PM, Mahon N, Davies MJ, WJ M. Relationship between myocyte disarray and outcome in hypertrophic cardiomyopathy[J]. Am J Cardiol,2001,88:275-279.
[16]Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2008,51(14):1369-1374.
[17]Moon JC, Mogensen J, Elliott PM, Smith GC, Elkington AG, Prasad SK, Pennell DJ, McKenna WJ. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin Ⅰ[J]. Heart,2005,91(8):1036-1040.
[18]Moon JCC, McKenna WJ, McCrohon J A, Elliott PM, Smith GC, Pennell D J. Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2003,41(9):1561-1567.
[19]Deborah H. Kwon, Randolph M. Setser, Zoran B. Popovic, Maran Thamilarasan, Srikanth Sola, Paul Schoenhagen, Mario J. Garcia, Scott D. Flamm, Harry M. Lever, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study.[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[20]Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy [J]. Circ Heart Fail,2008,1(3): 184-191.
[21]Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy:correlation with histopathology and prevalence of ventricular tachycardia[J]. J Am Coll Cardiol,2009,54(3):242-249.
[22]Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2012,5(4):370-377.
[23]McNamara MT, Tscholakoff D, Revel D, Soulen R, Schechtmann N, Botvinick E, CB H. Differentiation of reversible and irreversible myocardial injury by MR imaging with and without gadolinium-DTPA[J]. Radiology,1986,158(3):765-769.
[24]Wilson JM, Villareal RP, Hariharan R, Massumi A, Muthupillai R, SD F. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy [J]. Tex Heart Inst J,2002,29:176-180.
[25]Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2004,43(12): 2260-2264.
[26]Shirani J, Pick R, Roberts WC, BJ. M. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death[J]. J Am Coll Cardiol,2000,35:36-44.
[27]Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O'rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL, Klein WW, Priori SG, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy [J]. J Am Coll Cardiol, 2003,42(9):1687-1713.
[28]Maron B. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines[J]. Eur Heart J,2003,24(21):1965-1991.
[29]Heinrich G. Klues, Andrea Schiffers, Maron. BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy:Morphologic Observations and Significance As Assessed by Two-Dimensional Echocardiography in 600 Patients[J]. J Am Coll Cardiol,1995,36:1699-1708.
[30]Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy[J]. Circulation,1978,58(3):402-408.
[31]Andrew C.Y.To, Ashwat Dhillon, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2011,4(10):1123-1137.
[32]Noureldin RA, Liu S, Nacif MS, Judge DP, Halushka MK, Abraham TP, Ho C, Bluemke DA. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2012,14:17.
[33]Morton G, Chiribiri A, Ishida M, Hussain ST, Schuster A, Indermuehle A, Perera D, Knuuti J, Baker S, Hedstrom E, Schleyer P, O'Doherty M, Barrington S, Nagel E. Quantification of absolute myocardial perfusion in patients with coronary artery disease:comparison between cardiovascular magnetic resonance and positron emission tomography[J]. J Am Coll Cardiol,2012,60(16):1546-1555.
[34]Techasith T, Cury RC. Stress myocardial CT perfusion:an update and future perspective[J]. JACC Cardiovasc Imaging,2011,4(8):905-916.
[35]Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy[J]. J Thorac Cardiovasc Surg,2011,141(2):439-443.
[36]Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy[J]. Circ Heart Fail,2010,3(1): 51-58.
[37]O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11):867-874.
[38]Musat D, Marineci S, Sherrid MV. Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy?[J]. Prog Cardiovasc Dis,2012,54(6): 535-542.
[39]Menon SC, Eidem BW, Dearani JA, Ommen SR, Ackerman MJ, Miller D. Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents[J]. J Am Soc Echocardiogr,2009,22(12): 1327-1334.
[40]Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,56(11): 875-887.
[41]Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy [J]. Heart, 2012,98(6):438-442.
[42]Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement[J]. Magn Reson Med,2002,47(2):372-383.
[43]Salerno M, Kramer CM. Prognosis in hypertrophic cardiomyopathy with contrast-enhanced cardiac magnetic resonance:the future looks bright[J]. J Am Coll Cardiol,2010,56(11):888-889.
[44]Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy[J]. Am J Cardiol,2010,106(2): 261-267.
[45]Manuel D. Cerqueira, Neil J. Weissman, Vasken Dilsizian, Alice K. Jacobs, Sanjiv Kaul, Warren K. Laskey, Dudley J. Pennell, John A. Rumberger, Ryan T, Verani MS. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart:A Statement for Healthcare Professionals From the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2002,105(4):539-542.
[46]Nojiri A, Hongo K, Kawai M, Komukai K, Sakuma T, Taniguchi I, Yoshimura M. Scoring of late gadolinium enhancement in cardiac magnetic resonance imaging can predict cardiac events in patients with hypertrophic cardiomyopathy [J]. J Cardiol,2011,58(3):253-260.
[47]Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, Petryka J, Dabrowski M, Kepka C, Ruzyllo W. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy[J]. Eur J Radiol,2010,74(3):149-153.
[48]Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance[J]. JACC Cardiovasc Imaging, 2011,4(2):150-156.
[49]Buechel EV, Kaiser T, Jackson C, Schmitz A, Kellenberger CJ. Normal right-and left ventricular volumes and myocardial mass in children measured by steady state free precession cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson, 2009,11:19.
[50]Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M, Quarta G, Nistri S, Cecchi F, Salton CJ, Udelson JE, Manning WJ, Maron BJ. Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2008,52(7):559-566.
[51]Kwon DH, Smedira NG, Thamilarasan M, Lytle BW, Lever H, MY. D. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation[J]. J Thorac Cardiovasc Surg,2010,140(2):317-324.
[52]Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, Garcia MJ, Flamm SD, Lever HM, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study [J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[53]Ismail TF, Jabbour A, Mallorie A, Cowling T, Das B, Gulati A, Wage R, Pennell D, Prasad S. Role of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in the Risk Stratification of Hypertrophic Cardiomyopathy [J]. J Am Coll Cardiol,2012,59(13):E1581.
[54]Moon J, Cho IJ, Shim CY, Ha J-W, Jang Y, Chung N, Rim S-J. Abnormal Myocardial Capillary Density in Apical Hypertrophic Cardiomyopathy Can Be Assessed by Myocardial Contrast Echocardiography[J]. Circulation Journal,2010,74(10): 2166-2172.
[55]Ho KT, Chua KC, Klotz E, Panknin C. Stress and rest dynamic myocardial perfusion imaging by evaluation of complete time-attenuation curves with dual-source CT[J]. JACC Cardiovasc Imaging,2010,3(8):811-820.
[56]Munenobu Motoyasu, Kurita T, Katsuya Onishi, Shoko Uemura, Takashi Tanigawa, Tsutomu Okinaka, Kan Takeda, Takeshi Nakano, Masaaki Ito, Sakuma. H. Correlation Between Late Gadolinium Enhancement and Diastolic Function in Hypertrophic Cardiomyopathy Assessed by Magnetic Resonance Imaging[J]. Circ J, 2008,72:378-383.
[57]Giancarlo Todiere, Giovanni Donato Aquaro, Paolo Piaggi, Formisano F, Andrea Barison, Pier Giorgio Masci, Elisabetta Strata, Lorenzo Bacigalupo, Mario Marzilli, Alessandro Pingitore, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2012,60(10):922-929.
[58]Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy [J]. Eur Heart J,2009,30(16):2003-2010.
[59]Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy [J]. Hum Pathol,2013,44(1):133-141.
[60]Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2005,45(5):697-704.
[61]乔树宾.肥厚性心肌病-基础与临床[M].人民卫生出版社,2012.
[62]Sorajja P, Allison T, Hayes C, Nishimura RA, Lam CS, Ommen SR. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy [J]. Am J Cardiol,2012,109(10):1494-1498.
[63]Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy[J]. JACC Cardiovasc Imaging,2012,5(1):119-122.
[64]Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy [J]. Am J Cardiol,2011,107(4):604-608.
[65]Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy [J]. Int J Cardiol, 2011,152(2):258-259.
[66]Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM. Imaging phenotype versus genotype in hypertrophic cardiomyopathy[J]. Circ Cardiovasc Imaging, 2011,4(2):156-168.
[67]Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years:clinical perspectives [J]. J Am Coll Cardiol,2012,60(8): 705-715.
[1]Barry J. Maron, Maron MS. Hypertrophic cardiomyopathy[J]. The Lancet, 2013,381(9862):242-255.
[2]Noureldin RA, Liu S, Nacif MS, Judge DP, Halushka MK, Abraham TP, Ho C, Bluemke DA. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance[J]. J Cardiovasc Magn Reson,2012,14:17.
[3]Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy [J]. Circulation,1978,58(3):402-408.
[4]E, B, Lambrew CT, Rockoff SD, Ross J Jr, AG M. Idiopathic hypertrophic subaortic stenosis, I:a description of the disease based upon an analysis of 64 patients[J]. Circulation,1964,30:3-119.
[5]Wigle ED, Rakowski H, Kimball BP, WG. W. Hypertrophic cardiomyopathy: clinical spectrum and treatment[J]. Circulation,1995,92:1680-1692.
[6]Maron BJ. Hypertrophic cardiomyopathy an important global disease[J]. Am J Med,2004,116:63-66.
[7]Maron BJ. Hypertrophic cardiomyopathy a systematic review[J]. JAMA, 2002,287(10):1308-1320.
[8]Alcalai R, Seidman JG, CE S. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics[J]. J Cardiovasc Electrophysiol,2008,19:104-110.
[9]Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy:a personal history[J]. Circ Res,2011,108(6):743-750.
[10]Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy [J]. Circulation,2010,121(3): 445-456.
[11]Christph A. Nienaber, Sabine Hiller, Spielmann RP, Manfred Geriger, Kuck K-H. Syncope in hypertrophic cardiomyopathy Multivariate analysis of prognostic determinants[J].1990.
[12]Perry M. Elliott, Jan Poloniecki, Shaughan Dickie, Sanjay Sharma, Lorenzo Monserrat, Amanda Varnava, Niall G. Mahon, McKenna WJ. Sudden death in hypertrophic cardiomyopathy:Identification of High Risk Patients[J]. J Am Coll Cardiol, 2000,36(7):2212-2218.
[13]Stroumpoulis KI, Pantazopoulos IN, Xanthos TT. Hypertrophic cardiomyopathy and sudden cardiac death[J]. World J Cardiol,2010,2(9):289-298.
[14]Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, Nakajima T, Kawashiro N, Kawana M, Hagiwara N. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2011,57(23):2346-2355.
[15]Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, Abe Y, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy[J]. Magn Reson Imaging,2004,22(2):155-161.
[16]Kunihiko Teraoka, Masaharu Hirano, Ookubo H, Kazuyoshi Sasaki, Hiroaki Katsuyama, Masayuki Amino, Yimihiko Abe, Yamashina A. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy [J]. Magn Reson Imaging, 2005,23(5):701.
[17]Prinz C, Schwarz M, Ilic I, Laser KT, Lehmann R, Prinz EM, Bitter T, Vogt J, van Buuren F, Bogunovic N, Horstkotte D, Faber L. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy[J]. Can J Cardiol,2013,29(3):358-363.
[18]Frustaci A, Russo MA, Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy[J]. Hum Pathol,2013,44(1):133-141.
[19]Giancarlo Todiere, Giovanni Donato Aquaro, Paolo Piaggi, Formisano F, Andrea Barison, Pier Giorgio Masci, Elisabetta Strata, Lorenzo Bacigalupo, Mario Marzilli, Alessandro Pingitore, Lombardi M. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2012,60(10):922-929.
[20]Todiere G, Aquaro G, Pingitore A, Barison A, Strata E, Capozza P, Lombardi M. Progression of myocardial fibrosis and functional clinical status in Hypertrophic Cardiomyopathy:a study with cardiac magnetic resonance[J]. Journal of Cardiovascular Magnetic Resonance,2011,13(Suppl 1):P272.
[21]Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy[J]. Dtsch Arztebl Int,2011,108(13):209-215.
[22]Ho. CY. Hypertrophic Cardiomyopathy in 2012[J]. Circulation Journal, 2012,125:1432-1438.
[23]Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2009,54(3):220-228.
[24]Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy:from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2009,54(3):191-200.
[25]Michael J. Ackerman, Sara L. VanDriest, Steve R. Ommen, Melissa L. Will, Rick A. Nishimura, A. Jamil Tajik, J. B, Gersh BJ. Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy a comprehensive outpatient perspective [J]. J Am Coll Cardiol,2002,39(12):2042-2048.
[26]Niimura H BL, Sangwatanaroj S. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy[J]. N Engl J Med,1998,338:1248-1257.
[27]Van Driest SL, Ackerman MJ, SR O. Prevalence and severity of benign mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy [J]. Circulation,2002,106:3085-3090.
[28]Landstrom AP, MJ A. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy [J]. Circulation,2010,122:2441-2449.
[29]BJ Maron, SA Bodison, YE Wesley, E Tucker, Green. K. Results of screening a large group of intercollegiate competitive athletes for cardiovascular disease[J]. J Am Coll Cardiol,1987,10(6):1214-1221.
[30]Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years:clinical perspectives [J]. J Am Coll Cardiol,2012,60(8): 705-715.
[31]Dadlani GH, Harmon WG, Perez-Colon E, Sokoloski MC, Wilmot I, Lipshultz SE. Diagnosis and screening of hypertrophic cardiomyopathy in childrenfJ]. Progress in Pediatric Cardiology,2011,31(1):21-27.
[32]Colan SD. Hypertrophic cardiomyopathy in childhood[J]. Heart Fail Clin, 2010,6(4):433-444, vii-iii.
[33]Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2012,5(4):370-377.
[34]Schwartz PJ, Corrado D. Sudden Cardiac Death in Young Competitive Athletes[J]. Eur Heart J,2012,33(16):1986-1988.
[35]Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G.2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2011,58(25):e212-260.
[36]Colan SD. Treatment of hypertrophic cardiomyopathy in childhood[J]. Progress in Pediatric Cardiology,2011,31(1):13-19.
[37]Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia[J]. J Am Coll Cardiol,2012,60(20):1993-2004.
[38]Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy [J]. Heart, 2012,98(6):438-442.
[39]Shirley KW, Adirim TA. Sudden Cardiac Death in Young Athletes[J]. Clinical Pediatric Emergency Medicine,2005,6(4):194-199.
[40]Perry M. Elliott, Juan R. Gimeno, Maria T. Tome, Jaymin Shah, Deirdre Ward, Rajesh Thaman, Jens Mogensen, McKenna. WJ. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy [J]. Eur Heart J,2006,27:1933-1941.
[41]M Li, QB Wang, Cheng k. Long term follow-up results of 199 patients with hypertrophic cardiomyopathy [J]. Zhonghua Xin Xue Guan Bing Za Zhi,2007,35(11): 988-991.
[42]F Cecchi, A Sgalambro, M Baldi, B Sotgia, D Antoniucci, PG Camici, R Sciagra, Olivotto. I. Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy[J]. J Cardiovasc Transl Res, 2009,2(4):452-461.
[43]Jahnke C, Furundzija V, Gebker R, Manka R, Frick M, Schnackenburg B, Marx N, Paetsch I. Gender-based prognostic value of pharmacological cardiac magnetic resonance stress testing:head-to-head comparison of adenosine perfusion and dobutamine wall motion imaging[J]. Int J Cardiovasc Imaging,2012,28(5):1087-1098.
[44]Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, Schoenberg SO, Sueselbeck T, Germans T, Streitner F, Borggrefe M, Papavassiliu T. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy [J]. J Cardiovasc Magn Reson,2010,12:30.
[45]Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2008,51(14):1369-1374.
[46]Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B, Conte MR, Casazza F, Galderisi M, Maron BJ, Cecchi F. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy)[J]. Am J Cardiol,2006,98(7):960-965.
[47]Anwar AM, Soliman OI, Nemes A, Geleijnse ML, ten Cate FJ. An integrated approach to determine left atrial volume, mass and function in hypertrophic cardiomyopathy by two-dimensional echocardiography[J]. Int J Cardiovasc Imaging, 2008,24(1):45-52.
[48]Papavassiliu T, Germans T, Fluchter S, Doesch C, Suriyakamar A, Haghi D, Suselbeck T, Wolpert C, Dinter D, Schoenberg SO, van Rossum AC, Borggrefe M. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation[J]. J Cardiovasc Magn Reson,2009,11:34.
[49]Cecchi F. Does LV outflow tract obstruction increase the risk of sudden death in hypertrophic cardiomyopathy?[J]. Nat Clin Pract Cardiovasc Med,2007,4(4): 194-195.
[50]Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D, ten Cate FJ. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations[J]. JACC Cardiovasc Imaging,2009,2(1):58-64.
[51]Menon SC, Eidem BW, Dearani JA, Ommen SR, Ackerman MJ, Miller D. Diastolic dysfunction and its histopathological correlation in obstructive hypertrophic cardiomyopathy in children and adolescents [J]. J Am Soc Echocardiogr,2009,22(12): 1327-1334.
[52]Alia V, Koneru S, Reddy M, Fernandes J, Lakkireddy D, Hunter C, Mooss A. Delayed Contrast Enhancement on Cardiac Mri and Risk of Clinically Significant Ventricular Arrhythmias in Hypertrophic Cardiomyopathy:A Meta-Analysis of Observational Studies[J]. J Am Coll Cardiol,2012,59(13):E1226.
[53]赵世华.心血管病磁共振诊断学[M].人民军医出版社,2011.
[54]Uretsky S. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy [J]. Prog Cardiovasc Dis,2012,54(6):512-516.
[55]Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy [J]. Am J Cardiol,2011,107(4):604-608.
[56]Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, Weil J, Zenovich AG, Maron BJ. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy [J]. Circulation,2005,112(6):855-861.
[57]Moon JCC. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography[J]. Heart,2004,90(6):645-649.
[58]Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy [J]. Circulation,2008,118(15):1541-1549.
[59]Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart A, Council on Clinical Cardiology HF, Transplantation C, Quality of C, Outcomes R, Functional G, Translational Biology Interdisciplinary Working G, Council on E, Prevention. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention[J]. Circulation,2006,113(14):1807-1816.
[60]Rose A. Evaluation of pathological criteria for diagnosis of hypertrophic cardiomyopathy [J]. Histopathology,1984,8(3):395-406.
[61]MJ Davies, McKenna W. Hypertrophic cardiomyopathy--athology and pathogenesis[J]. Histopathology,1995,26(6):493-500.
[62]Turer AT, Samad Z, Valente AM, Parker MA, Hayes B, Kim RJ, Kisslo J, Wang A. Anatomic and clinical correlates of septal morphology in hypertrophic cardiomyopathy [J]. Eur J Echocardiogr,2011,12(2):131-139.
[63]Factor S, J Butany, MJ Sole, ED Wigle, WC Williams, Rojkind. M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,1991,17(6):1343-1351.
[64]Hughes SE. The pathology of hypertrophic cardiomyopathy [J]. Histopathology,2004,44:412-427.
[65]A. Ellims, L. lles, L. Ling, J. Hare, D. Kaye, Taylor A. Diffuse Myocardial Fibrosis in Hypertrophic Cardiomyopathy Identified by Cardiac Magnetic Resonance Imaging is Associated with Left Ventricular Diastolic Dysfunction[J]. Heart, Lung and Circulation,2012.
[66]E. Jacksona, N. Bellengerb, M. Seddonb, S. Hardena, Peebles C. Ischaemic and non-ischaemic cardiomyopathies-cardiac MRI appearances with delayed enhancement[J]. Clin Radiol,2007,62(5):395-403.
[67]Rehwald WG. Myocardial Magnetic Resonance Imaging Contrast Agent Concentrations After Reversible and Irreversible Ischemic Injury[J]. Circulation, 2002,105(2):224-229.
[68]Hanns-Joachim Weinmann, Robert C. Brasch, Wolf-R. Press, Wesbey. GE. Characteristics of gadolinium-DTPA complex a potential NMR contrast agent[J]. Am J Roentgenol,1984,142:619-624.
[69]Kim RJ, Judd RM, Chen EL, Fieno DS, Parrish TB, Lima JAC. Relationship of Elevated 23Na Magnetic Resonance Image Intensity to Infarct Size After Acute Reperfused Myocardial Infarction[J]. Circulation,1999,100(2):185-192.
[70]Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement[J]. Magn Reson Med,2002,47(2):372-383.
[71]Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy:correlation with histopathology and prevalence of ventricular tachycardia[J]. J Am Coll Cardiol,2009,54(3):242-249.
[72]Huang L, Han R, Ai T, Sun Z, Bai Y, Cao Z, Morelli JN, Xia L. Assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy:First-pass myocardial perfusion cardiovascular magnetic resonance imaging at 1.5 T[J]. Clin Radiol, 2013.
[73]Jordan N Andrew, Lyne Jonathan, Tom W. Unusual scarring patterns on cardiac magnetic resonance imaging-A potentially treatable etiology not to be missed[J]. Can J Cardiol,2010,26(4):el49-150.
[74]Lubna Choudhury, Heiko Mahrholdt, Anja Wagner, Kelly M. Choi, Michael D. Elliott, Francis J. Klocke, Robert O. Bonow, Robert M. Judd, Kim. RJ. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2002,40:2156-2164.
[75]Hiroshi Satoh, Fumitaka Matoh, Katsunori Shiraki, Takeji Saitoh, Keiichi Odagiri, Masao Saotome, Tsuyoshi Urushida, Hideki Katoh, Yasuo Takehara, Harumi Sakahara, Hayashi. H. Delayed enhancement on cardiac magnetic resonance and clinical, morphological, and electrocardiographical features in hypertrophic cardiomyopathy [J]. J Card Fail,2009,15(5):419-427.
[76]Moon JCC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance[J]. J Am Coll Cardiol,2003,41(9):1561-1567.
[77]Moon JC. What Is Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy?[J]. Revista Espanola de Cardiologia (English Edition),2007,60(1): 1-4.
[78]Moon JCC. Reed E. Sheppard MN, Elkington AG, Ho S, Burke M, Petrou M, Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2004,43(12): 2260-2264.
[79]Caitlin J. Harrigan, Evan Appelbaum, Barry J. Maron, Jacqueline L. Buros, C. Michael Gibson, John R. Lesser, James E. Udelson, Warren J. Manning, Maron MS. Significance of Papillary Muscle Abnormalities Identified by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy [J]. Am J Cardiol,2008,101(5):668-673.
[80]Kwon DH, Setser RM, Thamilarasan M, Popovic ZV, Smedira NG, Schoenhagen P, Garcia MJ, Lever HM, MY D. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. Heart,2007,94(10):1295-1301.
[81]Kwon DH, Smedira NG, Thamilarasan M, Lytle BW. Lever H, MY. D. Characteristics and surgical outcomes of symptomatic patients with hypertrophic cardiomyopathy with abnormal papillary muscle morphology undergoing papillary muscle reorientation[J]. J Thorac Cardiovasc Surg,2010,140(2):317-324.
[82]Andrew C.Y.To, Ashwat Dhillon, Desai MY. Cardiac magnetic resonance in hypertrophic cardiomyopathy [J]. JACC Cardiovasc Imaging,2011,4(10):1123-1137.
[83]Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW.2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:Executive Summary[J]. J Am Coll Cardiol,2011,58(25): 2703-2738.
[84]Hwang HJ, Choi EY, Kwan J, Kim SA, Shim CY, Ha JW, Rim SJ, Chung N, Kim SS. Dynamic change of mitral apparatus as potential cause of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy[J]. Eur J Echocardiogr, 2011,12(1):19-25.
[85]White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, Leong-Sit P, Warren H, Thompson T, Drangova M, Krahn A. Utility of cardiovascular magnetic resonance in identifying substrate for malignant ventricular arrhythmias[J]. Circ Cardiovasc Imaging,2012,5(1):12-20.
[86]Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy[J]. JACC Cardiovasc Imaging,2012,5(1):119-122.
[87]Ismail TF, Jabbour A, Mallorie A, Cowling T, Das B, Gulati A, Wage R, Pennell D, Prasad S. Role of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in the Risk Stratification of Hypertrophic Cardiomyopathy[J]. J Am Coll Cardiol,2012,59(13):E1581.
[88]Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, Garcia MJ, Flamm SD, Lever HM, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[89]Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy[J]. Circ Heart Fail,2008,1(3): 184-191.
[90]O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ, Prasad SK. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,56(11):867-874.
[91]Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11): 875-887.
[92]Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy [J]. Circ Heart Fail,2010,3(1): 51-58.
[93]Barry J. Maron, Julius M. Gardin, John M. Flack, Samuel S. Gidding, Tom T. Kurosaki, Bild. DE. Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults. Echocardiographic Analysis of 4111 Subjects in the CARDIA Study[J]. Circulation,1995,92:785-789.
[94]Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms[J]. J Am Coll Cardiol,2005,45(7):1076-1080.
[95]Bunch TJ, Chandrasekaran K, Ehrsam JE, Hammill SC, Urban LH, Hodge DO, Ommen SR, Pellikka PA. Prognostic significance of exercise induced arrhythmias and echocardiographic variables in hypertrophic cardiomyopathy [J]. Am J Cardiol, 2007,99(6):835-838.
[96]Deborah H. Kwon, Randolph M. Setser, Zoran B. Popovic, Maran Thamilarasan, Srikanth Sola, Paul Schoenhagen, Mario J. Garcia, Scott D. Flamm, Harry M. Lever, Desai MY. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy:a delayed contrast enhanced MRI study.[J]. Int J Cardiovasc Imaging,2008,24(6):617-625.
[97]Nazarian S, Lima JA. Cardiovascular magnetic resonance for risk stratification of arrhythmia in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol, 2008,51(14):1375-1376.
[98]Munenobu Motoyasu, Kurita T, Katsuya Onishi, Shoko Uemura, Takashi Tanigawa, Tsutomu Okinaka, Kan Takeda, Takeshi Nakano, Masaaki Ito, Sakuma. H. Correlation Between Late Gadolinium Enhancement and Diastolic Function in Hypertrophic Cardiomyopathy Assessed by Magnetic Resonance Imaging[J]. Circ J, 2008,72:378-383.
[99]Wayne J. S t, Trohman. RG, Martin Bilsker, Liaqat Zaman, Agustin Castellanos, Myerburg. RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,1986,7(3):701-704.
[100]Pujadas S, Vidal-Perez R, Hidalgo A, Leta R, Carreras F. Barros A, Bayes-Genis A, Subirana MT, Pons-Llado G. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy:a cardiac magnetic resonance imaging study [J]. Eur J Radiol,2010,75(2):88-91.
[101]乔树宾.肥厚性心肌病-基础与临床[M].人民卫生出版社,2012.
[102]Tani T, Yagi T, Kitai T, Kim K, Nakamura H, Konda T, Fujii Y, Kawai J, Kobori A, Ehara N, Kinoshita M, Kaji S, Yamamuro A, Morioka S, Kita T, Furukawa Y. Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy [J]. Cardiovasc Ultrasound,2011,9:34.
[103]Losi MA, Betocchi S, Barbati G, Parisi V, Tocchetti CG, Pastore F, Migliore T, Contaldi C, Caputi A, Romano R, Chiariello M. Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy [J]. J Am Soc Echocardiogr,2009,22(1):76-81.
[104]Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy [J]. Heart,2006,92(9):1339-1344.
[105]Jensen MK, Havndrup O, Hassager C, Helqvist S, Kelbaek H, Jorgensen E, Kober L, Bundgaard H. Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy [J]. Scand Cardiovasc J,2011,45(3):153-160.
[106]Butz T, Horstkotte D, Koerfer J, Langer C, Seggewiss H, Faber L, Assessment of myocardial scarring by contrast enhanced magnetic resonance imaging in a patient 11 years after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy [J]. Int J Cardiol,2010,145(1):e3-5.
[107]Chen S, Yuan J, Zhang J, Qiao S, Duan F, Lv X, Hu F, Yang W, Yang Y. Assessment of atrial conduction abnormalities in patients with hypertrophic cardiomyopathy before and one year after alcohol septal ablation[J]. Cardiology, 2012,123(4):254-260.
[108]Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, Svane B, Hansen TF, Kober L, Endresen K, Eriksson MJ, Jorgensen E, Amlie JP, Gadler F, Bundgaard H. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy:a Scandinavian multicenter study[J]. Circ Cardiovasc Interv,2011,4(3):256-265.
[109]Vogel-Claussen J, Santaularia Tomas M, Newatia A, Boyce D, Pinheiro A, Abraham R, Abraham T, Bluemke DA. Cardiac MRI evaluation of hypertrophic cardiomyopathy:left ventricular outflow tract/aortic valve diameter ratio predicts severity of LVOT obstruction[J]. J Magn Reson Imaging,2012,36(3):598-603.
[110]Fukuda S, Lever HM, Stewart WJ, Tran H, Song JM, Shin MS, Greenberg NL, Wada N, Matsumura Y, Toyono M, Smedira NG, Thomas JD, Shiota T. Diagnostic value of left ventricular outflow area in patients with hypertrophic cardiomyopathy:a real-time three-dimensional echocardiographic study[J]. J Am Soc Echocardiogr, 2008,21(7):789-795.
[111]Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, Kapadia SR. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,55(8):823-834.
[112]Marin F, Gimeno JR, Paya E, Garcia-Alberola A, Perez-Alvarez L Fernandez X, de la Morena G, Sogorb F, Castro-Beiras A, Valdes M, Martinez JG, Monserrat L. Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers [J]. Revista Espanola de Cardiologia (English Edition), 2006,59(6):537-544.
[113]Martin ET, Coman JA, Shellock FG, Pulling CC, Fair R, Jenkins K. Magnetic resonance imaging and cardiac pacemaker safety at 1.5-Tesla[J]. J Am Coll Cardiol,2004,43(7):1315-1324.
[114]Nazarian S, Roguin A, Zviman MM, Lardo AC, Dickfeld TL, Calkins H, Weiss RG, Berger RD, Bluemke DA, Halperin HR. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla[J]. Circulation,2006,114(12):1277-1284.
[115]Roguin A, Zviman MM, GR M. Modern pacemaker and implantable cardioverter defibrillator systems can be magnetic resonance imaging safe in vitro and in vivo assessment of safety and function at 1.5 T[J]. Circulation,2004,110(475-482).
[116]Sommer T, Naehle CP, A Y. Strategy for safe performance of extrathoracic magnetic resonance imaging at 1.5 tesla in the presence of cardiac pacemakers in non-pacemaker-dependent patients:a prospective study with 115 examinations[J]. Circulation,2006,114:1285-1292.
[117]Russo RJ, Costa H, Kabra A, Doud D, Uretsky S, Wolff S, Martin E, Machado C, Higgins S, Tominaga G, Florin T, Bloomgarden D, Birgersdotter-Green U, Ponce G, Schaerf R, Lampert R, Shah D, Arshad A, Anderson J, Tonkin A, Rivard A, Fyke F, Biederman R. Determining the Risks of Magnetic Resonance Imaging at 1.5 Tesla for Patients with Pacemakers and Implantable Cardioverter Defibrillators:The Magnasafe Registry[J]. J Am Coll Cardiol,2013,61(10):E810.
[118]Cohen JD, Costa HS, Russo RJ. Determining the risks of magnetic resonance imaging at 1.5 tesla for patients with pacemakers and implantable cardioverter defibrillators[J]. Am J Cardiol,2012,110(11):1631-1636.
[119]Dhandapany P, Sadayappan S, Xue Y, Powell G, Rani D, Nallari P, Rai T, Khullar M, Soares P, Bahl A. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia[J]. Nat Genet,2009,41:187-191.
[120]Girolami F, Ho C, Semsarian C, Baldi M, Will M, Baldini K, Torricelli F, Yeates L, Cecchi F, Ackerman M, Olivotto I. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations [J]. J Am Coll Cardiol,2010,55:1444-1453.
[121]Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, Nistri S, Sgalambro A, Grifoni C, Torricelli F, Camici PG, Cecchi F. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations [J]. J Am Coll Cardiol,2011,58(8):839-848.
[122]Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy[J]. Int J Cardiol, 2011,152(2):258-259.
[123]Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM. Imaging phenotype versus genotype in hypertrophic cardiomyopathy[J]. Circ Cardiovasc Imaging, 2011,4(2):156-168.
[124]Morita H, Nagai R, Seidman JG, Seidman CE. Sarcomere gene mutations in hypertrophy and heart failure[J]. J Cardiovasc Transl Res,2010,3(4):297-303.
[125]Hershberger RE. A glimpse into multigene rare variant genetics:triple mutations in hypertrophic cardiomyopathy [J]. J Am Coll Cardiol,2010,55(14): 1454-1455.